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Background:  The  pathogenesis  and  mechanisms  of  pain  in  osteoarthritis  (OA)  are  virtually  un-­




neuroplastic  changes  in  the  central  nervous  system  leading  to  hypersensitivity.  In  some  patients  
this  central  sensitization  is  sustained  and  is  believed  to  be  responsible  for  pain  persisting  after  
TKA.  The  search  for  analgesics  with  a  potential  of  preventing  acute  and  persistent  pain,  has  been  
GLUHFWHGQRWRQO\WRDJHQWVPLWLJDWLQJSDLQLQFRQMXQFWLRQZLWKVXUJHU\EXWDOVRWRDJHQWVWKDW
may  block  the  mechanisms  of  central  sensitization.  Tramadol,  a  weak  opioid  drug,  and  also  an  
inhibitor  of  the  reuptake  of  serotonin  and  norepinephrine,  has  been  suggested  for  prevention  of  
persistent  pain.
Aims:  The  aim  of  the  present  study  was  to  explore  preoperative  clinical  features  associated  with  
persistent  pain  after  TKA.  In  particular,   the  aim  was  to   test   the  predictive  value  of  separating  
pain  at  rest  from  pain  with  movement  with  regard  to  pain  relief  after  TKA.  Also  an  analysis  of  
radiological  and  histological  changes  in  relation  to  pain  at  rest  and  pain  with  movement  was  con-­
ducted.  Finally,  the  effect  of  intravenous  tramadol  100  mg  x  4,  given  during  24  hours  after  TKA,  
on  acute  postoperative  pain  and  persistent  pain  18  months  after  surgery  was  evaluated.
Results:  Preoperatively,  a  low  pain  threshold  to  electrical  stimulation  and  a  high  Visual  analogue  
scale  (VAS)  score  for  pain  at  rest,  but  not  with  movement,  was  found  to  predict  a  worse  outcome  
LQWHUPVRISDLQDWUHVWPRQWKVDIWHU7.$7KHJUDGHRIUDGLRJUDSKLF2$ZDVVLJQL¿FDQWO\
related  to  relief  of  pain  with  movement  from  preoperatively  to  18  months  postoperatively.  Best  
pain  relief  by  TKA  was  achieved  in  patients  with  severe  radiographic  changes.  The  combination  
of  intravenous  tramadol  100mg  x  4  and  morphine  via  patient  controlled  analgesia  (PCA)  pump  
did  not  offer  better  pain  relief  after  TKA  than  morphine  alone.  Nor  did  tramadol  prevent  persis-­
tent  pain  18  months  after  surgery.
Conclusions:  Pain   at   rest   should  not  be   a  prerequisite   for  TKA.   Instead,   a  high  preoperative  
score  for  pain  at  rest  and  a  low  pain  threshold  may  be  signs  of  central  sensitization  and  indicate  
an  increased  risk  of  persistent  postsurgical  pain.  Patients  scheduled  for  TKA  should  be  informed  
that  the  main  gain  to  expect  is  relief  of  pain  with  movement.  The  evaluation  of  the  outcome  af-­
ter  TKA  should  be  based  on  changes  in  pain  from  preoperatively  to  postoperatively,  instead  of  
PHUHO\FRQVLGHULQJSRVWRSHUDWLYHSDLQ0RVWLPSRUWDQWO\IROORZXSVWXGLHVRQSDLQUHOLHIE\MRLQW
replacement  should  separately  consider  pain  at  rest  and  pain  with  movement.  Tramadol  100mg  x  
4  given  intravenously  as  an  add-­on  to  morphine  during  24  hours  postoperatively  does  not  prevent  
acute  or  persistent  postoperative  pain  after  TKA.  
In  clinical  practice,  the  use  of  already  well-­established  diagnostic  tools  should  be  expanded  for  
the  purpose  of  identifying  patients  at  high  risk  of  persistent  pain  after  TKA.  Hopefully  this  could  
provide  guidelines  on  when  to  offer  pharmacological  prevention  of  persistent  postsurgical  pain  
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Musculoskeletal  disorders  are  the  most  common  cause  of  pain  (1).  The  prevalence  of  musculo-­
skeletal  pain  has  increased  between  two-­  and  fourfold  during  the  last  40  years  (2).  Osteoarthritis  
2$LVDPDMRUFDXVHRISDLQDQGGLVDELOLW\LQWKHHOGHUO\SRSXODWLRQ.  In  OA  the  knee  is  the  
PRVWFRPPRQO\DIIHFWHGMRLQWDQGDIUHTXHQWFDXVHRIGLVDELOLW\7KHSUHYDOHQFHRINQHH2$
increases  with  age  and  reaches  40-­60%  in  the  upper  seventies  (6).  
Neither  the  causes  of  OA  nor  the  sources  and  mechanisms  of  pain  are  fully  understood.  Conserva-­
tive  treatment  such  as  medication  and  physiotherapy  has  limited  effect  on  pain  and  progression  
of  the  disease  (7,  8).  Until  further  knowledge  about  the  pathogenesis  of  OA  and  mechanisms  of  
SDLQDUHREWDLQHGWRSHUPLWVSHFL¿FSKDUPDFRORJLFDOWDUJHWLQJVXUJLFDOWUHDWPHQWPRVWO\  remains  
WKHEHVWRSWLRQ7RWDONQHHDUWKURSODVW\7.$KDVDFRQVLVWHQWVLJQL¿FDQWHIIHFWLQWHUPVRISDLQ
relief  (9,  10).  
     
However,  TKA,   apart   from   causing   severe   acute   postoperative   pain,   entails   a   risk   of   serious  
complications  such  as  thrombo-­embolism  and  infection,  in  some  cases  even  prompting  amputa-­
WLRQ)XUWKHUPRUHWKHUHLVDVXESRSXODWLRQRISDWLHQWVXQGHUJRLQJMRLQWUHSODFHPHQWWKDW
experiences  persistent  unexplained  pain  (16-­18).  A  number  of  risk  factors  for  the  development  of  
SHUVLVWHQWSRVWVXUJLFDOSDLQKDYHEHHQLGHQWL¿HGThese  include  female  gender,  lower  age,  preop-­
erative  pain  (19),  psychic  vulnerability,  anxiety,  a  surgical  approach  causing  nerve  damage  and  
the  intensity  of  acute  postoperative  pain  (20,  21).  
In  the  search  for  the  sources  of  pain  many  attempts  have  been  made  to  correlate  radiographic  
features  of  OA  with  pain  (22,  23)  but   the  ¿QGLQJVUHPDLQFRQWUDGLFWRU\$OWKRXJKLWKDVEHHQ
reported  that  the  risk  of  knee  pain  increases  with  the  radiographic  severity  of  OA  (24,  25),  many  
patients  with  radiographic  OA  do  not  have  pain  (26).  It  has  been  suggested  WKDWV\QRYLDOLQÀDP-­
mation  and/or  increased  intraosseous  pressure  cause  pain  in  OA  (27).  Increasing  evidence  has  
also  accumulated  about  central  and  peripheral  mechanisms  leading  to  sensitization  of  neurons  
DQGUHFHSWRUVOHDYLQJQRWRQO\WKHDIIHFWHGMRLQWEXWDOVRGLVWDQWVLWHVmore  sensitive  to  normally  
innocuous  stimuli  (5,  28).
        
,GHQWL¿FDWLRQRISUHRSHUDWLYHSDWLHQWFKDUDFWHULVWLFVDVVRFLDWHGZLWKDQLQFUHDVHGULVNRISHUVLVWHQW
pain  after  TKA  can  be  expected  to  improve  the  selection  criteria.  This  prompted  an  investigation  
of  the  predictive  value  of  preoperative  pain,  pain  thresholds,  and  grade  of  radiographic  and  histo-­
logical  changes  in  relation  to  postoperative  pain.
  
3UHYHQWLYHDQDOJHVLDLVDWHUPXVHGIRUSDLQPDQDJHPHQWLQFRQMXQFWLRQZLWKVXUJHU\DLPHGDWUH-­
ducing  the  incidence  of  persistent  postsurgical  pain.  Tramadol  has  been  suggested  as  a  compound  
with  a  potential  to  prevent  acute  postoperative  pain  as  well  as  persistent  postsurgical  pain  (29).  







Osteoarthritis  (OA)  is  a  chronic  irreversible  condition  characterized  by  destruction  of  articular  
cartilage  and  subchondral  bone.  The  underlying  cause  of  degeneration  can  be  attributed  to  several  
factors.  OA  is  commonly  divided  into  primary  and  secondary  OA.  In  primary  OA,  which  usu-­
ally  develops  at  the  age  of  55-­60  years,  the  underlying  cause  is  unknown,  possibly  genetically  
ZKHUHDVLQVHFRQGDU\2$WKHFDXVHLVXVXDOO\LGHQWL¿HG5LVNIDFWRUVIRUGHYHORSPHQWRIVHFRQG-­
DU\2$DUHLQMXULHVREHVLW\LQDFWLYLW\PDOIRUPDWLRQVDQGKDHPRSKLOLD6HFRQGDU\2$XVXDOO\
develops  at  an  earlier  age.
The  pathogenesis  of  OA  has  long  been  thought  to  be  cartilage  driven(32),  starting  with  focal  areas  
of  damage  to  the  cartilage.  In  an  attempt  of  repair,  chondrocytes  form  clusters  in  the  damaged  
areas  and  the  concentration  of  growth  factors  in  the  matrix  increase.  This  attempt  subsequently  
fails  and  leads  to  an  imbalance  in  favour  of  degradation.  Increased  synthesis  of  tissue-­destructive  
proteinases,  increased  apoptotic  death  of  chondrocytes  and  inadequate  synthesis  of  components  
of  the  extra  cellular  matrix  lead  to  the  formation  of  a  matrix  that  is  unable  to  withstand  normal  
mechanical  stress  (32).  
Recent  evidence  (33)  shows  an  additional  and  integrated  role  of  bone  and  synovial  tissue.  The  
initial  signs  of  OA  are  changes  in  the  subchondral  bone.  Osteophyte  formation,  bone  remodelling,  
subchondral  sclerosis,  and  attrition  are  crucial  for  radiological  diagnosis  (32).  Several  of  these  
ERQHFKDQJHVWDNHSODFHQRWRQO\GXULQJWKH¿QDOVWDJHRIWKHGLVHDVHEXWDOVRDWWKHRQVHWRIWKH
GLVHDVHSRVVLEO\EHIRUHFDUWLODJHGHJUDGDWLRQ7KLV¿QGLQJOHGWRWKHVXJJHVWLRQWKDWVXEFKRQGUDO
bone  changes  could  initiate  cartilage  damage.
  
PAIN  MECHANISMS  IN  OA
Pain
The  ability  to  experience  pain  is  an  important  advantage  in  the  evolution.  Responding  adequately  
to  a  painful  stimulus  protects  the  body  from  further  damage.  Patients  who  are  unable  to  perceive  
SDLQIURPHJMRLQWVDVLQWKHKHUHGLWDU\GLVHDVH³1RUUERWWQLDQFRQJHQLWDOLQVHQVLWLYLW\WRSDLQ´
HQGXSZLWKVHYHUHGHVWUXFWLRQRIWKHODUJHMRLQWV7KLVFOHDUO\KLJKOLJKWVWKHSURWHFWLYHIXQF-­
tion  of  the  nervous  system.
7KH,QWHUQDWLRQDO$VVRFLDWLRQIRUWKH6WXG\RI3DLQGH¿QHVSDLQDV³DQXQSOHDVDQWVHQVRU\DQG
emotional  experience  associated  with  actual  or  potential  tissue  damage,  or  described  in  terms  of  
VXFKGDPDJH´www.iasp-­pain.org 7KHIDFW WKDWSDLQ LVDQ LQGLYLGXDOH[SHULHQFH LQÀX-­
enced  not  only  by  psychosocial  factors  but  also  by  previous  experiences,  inevitably  makes  inter-­
individual  comparison  of  pain  scores  questionable.
'HVSLWHFRQVLGHUDEOHHIIRUWVWKHPHFKDQLVPVRISDLQLQ2$VWLOOUHPDLQWREHIXOO\FODUL¿HG$
number  of  observations  have  contributed  to  the  elusiveness  of  pain  in  OA.  Firstly,  not  all  OA  
patients  experience  pain.  Secondly,  pain  can  be  reduced  by  placebo  surgery  and  thirdly  a  consid-­
HUDEOHQXPEHURISDWLHQWVXQGHUJRLQJVHHPLQJO\DGHTXDWHMRLQWUHSODFHPHQWVGHYHORSSHUVLVWHQW
pain.  It  has  been  reported  that  the  risk  of  knee  pain  increases  with  the  radiographic  severity  of  
OA  (24,  25).  Yet,  many  with  radiographic  OA  do  not  have  pain  (26).  In  some  studies  it  has  been  
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VKRZQWKDWORFDODQGV\VWHPLFLQÀDPPDWRU\IHDWXUHVDUHVLJQL¿FDQWO\UHODWHGWRSDLQZKHUHDV
other  studies  have  failed  to  demonstrate  such  relationships  (37-­39).    The  poor  correlation  can  be  
attributed  to  several  causes,  involving  the  sensitivity  of  radiographs  to  quantify  the  disease,  the  
heterogeneity  of  the  disease  process  and  an  individual’s  interpretation  and  behaviour  towards  a  
potentially  painful  stimulus  (35).  
Nociception
Nociception   is   a  neurophysiologic   term   that  describes   the  activity   in  a  nerve  pathway,  which  
transmits  signals  from  a  potentially  noxious  stimulus,  but  is  not  always  perceived  as  painful  (35).  
3DLQLVWKHVXEMHFWLYHH[SHULHQFHWKDWDFFRPSDQLHVQRFLFHSWLRQEXWFDQDOVRDULVHZLWKRXWDVWLPX-­
lus.  Nociceptive  pain  arises  from  actual  or  threatening  damage  to  non-­neural  tissue  and  is  due  to  
WKHDFWLYDWLRQRIQRFLFHSWRUV,PSXOVHVRIVXI¿FLHQWLQWHQVLW\IURPWKHQRFLFHSWLYH¿EUHVZLOO
produce  post-­  synaptic  depolarisation  in  the  spinal  neurons  after  synapses  in  the  dorsal  horn.  Via  
one  of  four  spinal  tracts  the  impulse  is  then  transmitted  to  the  supra-­spinal  pain  matrix  consisting  
of  nuclei  of  the  thalamus,  hypothalamus,  cerebellum,  cerebral  cortex,  medulla,  and  brain  stem.







aching  pain  (35).  In  peripheral  and  central  neuropathic  pain  conditions  the  A-­β¿EUHVDUHWKRXJKW
to  be  responsible  for  allodynia  i.e.  pain  due  to  a  stimulus  that  does  not  normally  provoke  pain  
(41).  
,Q%MXUKROPGHYHORSHGDPHWKRGIRUGHPLQHUDOL]DWLRQRIERQHZKLOHSUHVHUYLQJWKH
antigenicity  of  neuroactive  peptides.  In  this  way  nerves  could  be  demonstrated  by  immunohis-­
WRFKHPLFDOVWDLQLQJ7KLVSHUPLWWHGLGHQWL¿FDWLRQRIQHUYH¿EUHVDFFRUGLQJWRVSHFL¿FVHQVRU\
and  autonomic  mediators.  The  neuropeptides  were  predominantly  found  in  vascular  structures,  
but  free  nerve  endings  were  also  seen  in  all  parts  of  long  bones,  the  highest  abundance  being  in  
areas  with  high  osteogenic  activity.  
  
7RLQYHVWLJDWHZKHWKHUERQHWLVVXHPD\EHDVRXUFHRINQHHSDLQLQMHFWLRQRIOLTXLGLQWRWKHSD-­
tella  has  been  tested  and  found  to  be  very  painful  suggesting  that  increased  intra-­osseous  pressure  
can  be  a  cause  of  pain  in  OA.  Further  support  of  this  observation  is  that  the  appearance  of  bone  
marrow  lesions  (43)  on  magnetic  resonance  images  (MRI)  is  associated  with  pain.  On  histologi-­
FDOH[DPLQDWLRQWKHVHDUHDVVKRZDEQRUPDOERQHZLWKH[FHVVLYH¿EURVLVVPDOODUHDVRIRVWHRQH-­
crosis,  and  extensive  bone  remodelling.  Other  features  on  MRI  that  have  been  related  to  pain  are  
knee  effusions  and  synovial  thickening.  
Ahmed  and  colleagues  (44)  investigated  the  distribution  of  sensory  and  autonomic  neuropeptides  
LQMRLQWWLVVXHDQGIRXQGHYLGHQFHIRUDQLQYROYHPHQWRIWKHQHUYRXVV\VWHPLQLQÀDPPDWRU\MRLQW






Studies  on  un-­anesthetized  patients  (45)  have  shown  that  the  most  pain  sensitive  structures  in  the  
knee  are  ligament  insertions,  synovium  and  the  fat  pad  underneath  the  patellar  tendon.  However,  
the  cartilage  itself  was  not  tender  in  these  studies.  As  the  synovial  membrane  is  richly  innervated  
LWLVEHOLHYHGWREHUHVSRQVLEOHIRUWKHSDLQIXOÀDUHVRI2$WKDWFDXVHVWKHWHPSRUDOYDULDWLRQ
of  pain  in  OA.  
  
One  reason  for  the  contradictory  results  in  studies  of  morphologic  features  and  pain  in  OA  could  
be   that   pain   at   rest   and  pain  with  movement   partly   have  different  mechanisms   and   therefore  
VKRXOGEHFRQVLGHUHGVHSDUDWHO\)XUWKHUPRUHGXHWRWKHVXEMHFWLYHQDWXUHRISDLQLQWHULQGLYLG-­
ual  comparison  of  pain  scores  can  be  questionable,  whereas  intra-­individual  comparison  of  pain  
over  time  may  prove  to  offer  more  relevant  information.     
Figure  1..QHH2$DVVHHQGXULQJ7.$ZLWKV\QRYLDOLQÀDPPDWLRQRVWHRSK\WHVFDU-­




OA  can  be  detected  by  MRI,  ultrasound,  and  by  analysis  of  biological  markers  in  blood  or  syno-­
YLDOÀXLG$PRQJGLIIHUHQWPHWKRGVRIGHWHFWLQJDQGJUDGLQJV\QRYLWLVKLVWRORJLFDOH[DPLQD-­
WLRQRIELRSV\REWDLQHGVDPSOHVLVFRQVLGHUHGWKH³JROGVWDQGDUG´7KHKLVWRORJLFDOFKDQJHV
that  occur  in  the  OA  synovium  include  hypertrophy  and  hyperplasia  with  an  increase  in  the  num-­
EHURIV\QRYLDOOLQLQJFHOOV7KHVHFKDQJHVDUHRIWHQDFFRPSDQLHGE\LQ¿OWUDWLRQRIPRQRQXFOHDU







matory  mediators  such  as  cytokines,  nitric  oxide,  prostaglandin  E2  and  neuropeptides  are  pro-­
GXFHGE\WKHLQÀDPHGV\QRYLXPDQGDOWHUWKHEDODQFHRIFDUWLODJHPDWUL[GHJUDGDWLRQDQGUHSDLU
leading  to  excess  production  of  proteolytic  enzymes  responsible  for  cartilage  breakdown.  Deg-­
UDGDWLRQSURGXFWVIURPWKHFDUWLODJHLQWXUQDPSOLI\V\QRYLDO LQÀDPPDWLRQFUHDWLQJDYLFLRXV
circle.  Macrophages  have  also  been  shown  to  mediate  synovitis  and  angiogenesis  in  OA  by  the  
UHOHDVHRI9DVFXODUGHULYHG(QGRWKHOLDO*URZWK)DFWRU9(*),QUHVSRQVHWRLQÀDPPDWLRQ
of  the  synovial  membrane  and  continuous  nociceptive  input,  peripheral  nerve  endings  become  
more  sensitive  to  incoming  stimulus,  i.e.  peripheral  sensitization.  
Peripheral  sensitization
After  tissue  trauma,  pain  occurs  through  noxious  stimulation  of  afferent  nerves.  In  response  to  
GDPDJHG WLVVXH UHOHDVLQJ LQÀDPPDWRU\PHGLDWRUVVXFKDVF\WRNLQHVDQGSURVWDJODQGLQVDW WKH
ZRXQGVLWHDUHGXFWLRQLQWKUHVKROGDQGDPSOL¿FDWLRQLQWKHUHVSRQVLYHQHVVRFFXUVLQSHULSKHUDO
terminals  of  high  threshold  primary  sensory  neurons  (50,  51).  This  process,  peripheral  sensitiza-­
WLRQFDXVHVDSULPDU\PHFKDQLFDOK\SHUDOJHVLDWKDWLVUHVWULFWHGWRWKHVLWHRIWLVVXHLQMXU\DQGLV
thought  to  be  adaptive  in  the  sense  that  it  protects  the  body  from  further  damage.  
Central  sensitization
Central  sensitization  is  an  enhancement  of   the  function  of  neurons  and  circuits   in  nociceptive  
SDWKZD\VFDXVHGE\LQFUHDVHGPHPEUDQHH[FLWDELOLW\DQGV\QDSWLFHI¿FDF\DVZHOODVUHGXFHG
inhibition.  This  represents  an  adaptive  plasticity  of  the  nervous  system  in  response  to  activity,  
LQÀDPPDWLRQDQGQHXUDOLQMXU\)RXUPHFKDQLVPVDUHFRQVLGHUHGRISDUWLFXODULPSRUWDQFH
changes  in  the  expression  of  sodium  ion  channels,  up  regulation  of  calcium  ion  channels,  activa-­
tion  of  NMDA  receptors  and  disinhibition.
&RQWLQXRXVDQGLQWHQVHQRFLFHSWLYHLQSXWIURPDGDPDJHGMRLQWPD\GULYHFHQWUDOVHQVLWL]DWLRQ
assumed  to  play  an  important  role  in  OA  (5).  In  addition,  enhanced  central  summation  may  fa-­
cilitate  temporal  summation  in  OA  patients  as  seen  in  other  patients  with  chronic  musculoskeletal  
pain.  Another  indicator  of  central  sensitization  is  more  intense  pain  and  larger  areas  of  referred  
pain  in  response  to  experimental  muscle  stimulation  (52).  
  
,QRUGHUWRGHPRQVWUDWHFHQWUDOVHQVLWL]DWLRQSDWLHQWVSHFL¿FWHVWVKDYHEHHQGHYHORSHG%\PHD-­
suring  pressure  pain  thresholds  at  many  sites  around  the  knee,  spreading  sensitization,  temporal  
summation  of  pressure  pain,   pain   responses   and   referred  pain   areas   after   intra-­muscular   pain  
stimulation  and  the  potency  of  diffuse  noxious  inhibitory  control  (DNIC),  signs  of  central  sensi-­
tization  have  been  demonstrated  among  patients  with  OA  (5).  Treatment  of  neuropathic  pain  has  
DOVREHHQVKRZQWREHHIIHFWLYHLQ2$>@+RZHYHUUHYHUVLQJLQÀDPPDWLRQLQWKHSHULSKHUDO
tissue  does  not  always  attenuate  central  sensitization.  Therefore  refractory  pain  may  persist  even  
after  TKA  (53).  The  importance  of  central  sensitization  in  OA  has  been  highlighted  by  Arendt-­
Nielsen  (5)  and  it  has  also  been  suggested  as  a  mechanism  in  chronic  or  persistent  postsurgical  
SDLQ3DLQDWUHVWKDVEHHQVXJJHVWHGWRUHÀHFWDQHXURSDWKLFFRPSRQHQWZKLFKKRZHYHUVWLOO




ASSESSMENT  OF  PAIN  IN  OA
Pain  
Pain  is  a  personal  experience  and  an  individual  interpretation  of  a  nociceptive  stimulus  that  is  
LQÀXHQFHGE\SUHYLRXV H[SHULHQFHV DQGSV\FKRVRFLDO IDFWRUV2EMHFWLYH LQWHULQGLYLGXDO FRP-­
parison  of  pain  measurements   is   therefore  virtually   impossible.  Nonetheless,  pain   is   the  most  
important  symptom  of  OA  and  the  main  indication  for  surgery.  In  clinical  practice  and  research  
WKHUHLVDQHHGIRUUHOLDEOH\HWVLPSOHWRROVIRUPHDVXULQJSDLQLQWHQVLW\7KHGLI¿FXOWLHVZLWKSDLQ
PHDVXUHPHQWVDUHUHÀHFWHGE\WKHPXOWLWXGHRISDLQVFRULQJV\VWHPVDYDLODEOH3DLQLQWHQVLW\FDQ
be  assessed  with  numerical  rating  scales,  verbal  descriptor  scales  as  the  Likert  scale  or  visual  ana-­
logue  scales  (VAS)  (55)  each  of  which  has  its  advantages  and  drawbacks.  Another  generic  scale  
is  the  Borg  CR-­10  scale  (56),  which  takes  into  account  that  pain,  increases  in  a  logarithmic  rather  
than  linear  fashion.  The  quality  of  pain  is  considered  in  the  McGill  Pain  Questionnaire  (MPQ)  
ZKLFKUHÀHFWVWKHVHQVRU\DIIHFWLYHDQGHYDOXDWLYHGLPHQVLRQVRISDLQ
VAS
The  use  and  validity  of  VAS  for  pain  assessment  have  been  reported  previously  (58,  59).  Patients  
move  a  vertical  line  along  the  scale  and  select  a  position  on  a  100  mm  line  that  corresponds  to  the  
intensity  of  their  pain.  The  left  endpoint  represents  no  pain,  whereas  the  right  endpoint  depicts  the  
worst  imaginable  pain.  The  ratings  on  the  back  of  the  scale  are  read  and  recorded  as  numbers  from  
WR,QFOLQLFDOSUDFWLFHWKH9$6LVRIWHQVLPSOL¿HGE\UHFRUGLQJWKHVFRUHVDVZKROHQXPEHUV
between  0  and  10,  Figure  2.  The  accuracy  of  pain  measurements  is  impossible  to  determine,  as  
WKHUHVSRQVHLVDIIHFWHGQRWRQO\E\WKH³WUXH´SDLQLQWHQVLW\EXWDOVRE\WKHSDWLHQWVLQWHUSUHWDWLRQ
of  this  sensation.  In  a  recent  study  the  test–retest  reliability  of  two  consecutive  pain  scores  on  the  
9$6ZDVIRXQGWREHH[FHOOHQWZLWKDQLQWUDFODVVFRUUHODWLRQFRHI¿FLHQWRIU 
Figure  2.  The  Swedish  version  of  VAS  used  for  assessment  of  pain  intensity  in  this  thesis  
XSSHU¿JXUHLVWKHVLGHIDFLQJWKHSDWLHQWDQGWKHORZHU¿JXUHLVWKHEDFNVLGHRIWKHGHYLFH
'LVHDVHVSHFL¿FVFDOHV
The  WOMAC  index  of  OA  is  the  most  widely  used  score  for  assessing  pain  and  progression  of  
the  disease  (61)  and  is  recommended  by  the  World  Health  Organization  (WHO).  It  includes  24  
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items  divided  into  three  categories:  pain,  stiffness,  and  function.  Although  data  on  pain  at  rest  and  
pain  during  different  activities  are  collected  separately  in  the  WOMAC  index,  most  authors  pres-­
ent  the  scores  from  the  pain  domain  as  one  global  index  on  a  scale  from  0  to  20.  Other  disease  
VSHFL¿FVFDOHVDUHWKH.QHH6RFLHW\6FRUHWKH,.'&WKH2[IRUG.QHH6FRUHDQGWKH.226
These  are  all  available  on  the  Internet  at  www.orthopaedicscores.com.    
Quantitative  sensory  testing  (QST)
Quantitative  sensory  testing  (QST)  is  a  term  used  to  describe  psychophysical  methods  of  determin-­
ing  thresholds  or  stimulus  response  curves  for  sensory  processing  under  normal  and  pathophysio-­
logical  conditions.  By  recording  participant’s  responses  to  external  stimuli  of  controlled  intensity  
467DOORZVXVWRJHWDQXPHULFDOYDOXHRIDVSHFL¿FVHQVRU\SHUFHSWLRQ$VYDULRXVPRGDOLWLHV
RIVWLPXOXVDIIHFWGLIIHUHQWQHUYH¿EUHV467FDQDOVREHXVHGWRWHVWQHUYH¿EUHVVHSDUDWHO\'LI-­
ferent  methods  for  detection  of  sensory  and  pain  thresholds  as  well  as  suprathreshold  and  pain  
tolerance  thresholds  have  been  introduced.  Common  physical  stimuli  include  warmth  and  cool-­
ness,  heat  pain,  touch-­pressure,  and  vibration.  A  simple  method  recently  introduced  is  the  Pain  
Matcher®  (Figure  3),  an  electrocutaneous  stimulator,  which  has  been  validated  for  assessment  of  
pain  and  detection  of  sensory  thresholds  (62).  








Electrocutaneous  stimulation  is  used  for  measurement  of  current  perception  thresholds  and  pain  
tolerance  thresholds.  Neuroselectivity  is  achieved  by  using  different  frequencies:  5  Hz  stimulates  
VPDOOXQP\HOLQDWHG&¿EUHV+]VWLPXODWHV$į¿EUHVDQGWKH+]IUHTXHQF\LVQHX-­
URVHOHFWLYHWRZDUGVWKHODUJHP\HOLQDWHG$ȕ¿EUHV7KHPDLQGLIIHUHQFHEHWZHHQHOHFWULFDODQG
thermal-­mechanical  stimuli  is  that  electrical  stimuli  bypass  peripheral  nociceptors  (64).  Notably,  
pain  thresholds  measured  by  the  Pain  Matcher®  have  been  shown  to  predict  the  intensity  of  post-­
operative  pain  after  caesarean  section  (65).  It  has  been  reported  that  electrical  stimulation  can  












been  criticized  because  of  its  emphasis  on  the  presence  of  osteophytes  and  inability  to  separate  
GLIIHUHQWUDGLRJUDSKLFIHDWXUHVLQWKHFODVVL¿FDWLRQ$OWKRXJKWKHUHSURGXFLELOLW\KDVEHHQYDULDEOH
it  was  concluded  in  a  study  by  Kessler  (70)  that  so  far  no  other  system  shows  higher  reliability.  
,Q$KOElFNLQWURGXFHGDVLPSOHV\VWHPIRUWKHFODVVL¿FDWLRQRIRVWHRDUWKULWLFFKDQJHVRQD
SODLQUDGLRJUDSK$OWKRXJKKLVV\VWHPKDVEHHQFULWLFL]HGIRUGLI¿FXOWLHVLQGLVFULPLQDWLQJ
low  from  medium  stages,  its  reliability  is  probably  quite  good  when  using  optimal  radiographic  
positioning  and  an  experienced  radiologist  (73).  Weidow  et  al.  (74)  found  poor  reproducibility  
DQGYDOLGLW\LQWKH$KOElFNVFDOHDVFRPSDUHGWRYLVXDOLQVSHFWLRQRIWKHMRLQWSUHRSHUDWLYHO\
Nonetheless,   the   intra-­observer   reliability   as  well   as   the   sensitivity   of   the  Ahlbäck   scale  was  
found  to  be  acceptable  in  the  same  study.
  
3ODLQUDGLRJUDSK\LVVWLOOWKH³ZRUNKRUVH´LQWKHFOLQLFDOGLDJQRVLVRI2$+RZHYHUZLWKWKHLQ-­
creasing  availability  of  MRI,  many  patients  referred  to  an  orthopaedic  surgeon  have  already  been  
investigated  by  MRI.  For   research  purposes   the  Osteoarthritis  Research  Society   International  
2$56,LQLWLDWHGDZRUNLQJJURXSWKDWVWDWHGWKDWPHDVXUHPHQWRINQHHMRLQWVSDFHZLGWK
obtained  from  plain  radiography  was  reliable.  However,   they  also  concluded  that  MRI  is  best  
for  imaging  of  osteoarthritis  because  of  its  unique  ability  to  visualize  multiple  individual  tissue  
pathologies  related  to  pain.  Thus,  future  research  efforts  in  imaging  of  osteoarthritis  are  likely  
to  shift  further  from  conventional  radiography-­based  studies  to  those  that  directly  visualize  the  
WDUJHWWLVVXHVVSHFL¿FDOO\05,DQGSRVVLEO\DOVRXOWUDVRXQG
NON-­SURGICAL  TREATMENTS  OF  KNEE  PAIN  IN  OA
The  magnitudes  of  the  effect  of  available  therapies  for  the  management  of  hip  and  knee  OA  have  
been  determined  by  systematic  literature  search  (77)  of  the  Osteoarthritis  Research  Society  In-­
ternational  (OARSI).  The  effect  size  (ES)  is  calculated  by  dividing  the  mean  difference  between  
treatments  by  the  standard  deviation  of  the  difference.  It  is  therefore  suitable  for  non-­parametric  
cross-­study  comparisons.  An  effect  size  of  0.2  is  considered  small,  whereas  0.5  is  moderate  and  

















etamol.  However,  the  use  of  oral  NSAIDs  is  sometimes  not  possible  because  of  the  well-­known  
gastrointestinal  and  cardiovascular  side  effects.  It  has  also  been  proposed  that  NSAIDs  may  ac-­
celerate  the  course  of  OA  (80)  due  to  a  toxic  effect  on  articular  cartilage  (81).  Opioid  drugs  have  
DPRGHUDWHWRODUJHHIIHFW(6 RQSDLQLQWHQVLW\+RZHYHUWKHXVHRIRSLRLGVKDVLWVOLPLWD-­
tions  due  to  side  effects  such  as  nausea,  constipation,  dizziness,  and  somnolence.  
  
Recently  the  dietary  supplements  glucosamine-­  and  chondroitin  sulphate  have  been  introduced  
for  the  treatment  of  OA.  Although  some  evidence  from  animal  models  (82)  and  clinical  studies  
indicate  that  administration  of  glucosamine  sulphate  may  delay  radiological  progression  of  knee  
OA  (83,  84),  this  remains  controversial.  Furthermore  these  compounds  have  only  limited,  if  any,  
HIIHFWRQSDLQ(6 
,QWUDDUWLFXODU VWHURLGV VHHP WRKDYH DJRRGHIIHFW RQSDLQ (6 +RZHYHU WKLV WHQGV WR
GHFUHDVHIRUHDFKLQMHFWLRQZLWKQRHIIHFWDWDOODIWHUWZR\HDUV,QWUDDUWLFXODUK\DOXURQLFDFLG
seems  to  have  a  longer  lasting  effect  on  pain  than  cortisone  with  an  ES  of  up  to  0.60.  However,  in  
a  Cochrane  report  from  2009  (87)  it  was  concluded  that  available  treatment  options  for  OA  have  
limited  analgesic  effects  and  that  there  is  an  urgent  need  for  more  effective  treatments  in  OA.  
Increasing  evidence  of  central  sensitization  in  patients  with  chronic  osteoarthritic  pain  (5)  has  
lead  to  the  use  of  pharmacological  agents  acting  on  supraspinal  pathways.  Agents  that  have  been  
tried  with  positive  effects   in  osteoarthritis  are  ketamine,  gabapentin,   imipramine,  venlafaxine,  
and  duloxetine  (88).  Venlafaxine  and  duloxetine  are  inhibitors  of  serotonin  and  norepinephrine  
UHXSWDNHDQGDUHDOVRXVHGLQWKHWUHDWPHQWRIGHSUHVVLRQDQG¿EURP\DOJLD.HWDPLQHLVDQ10'$
antagonist  whereas  the  exact  mechanisms  of  action  for  gabapentin  remain  unknown.  Ketamine,  
gabapentin,  and  imipramine,  have  all  been  shown  to  inhibit  temporal  summation,  which  is  a  key  
feature  in  the  initiation  of  central  sensitization.
Tramadol
Tramadol  [2-­(dimethylaminomethyl)-­1-­(3-­methoxyphenyl)  cyclohexanol],  developed  in  the  late  
1970’s  is  a  centrally  acting  analgesic  drug  used  to  treat  moderate  pain.  Tramadol  is  increasingly  
used  for  the  treatment  of  OA  because,  in  contrast  to  NSAIDs  (89,  90),  it  does  not  cause  gastro-­
intestinal  bleeding  or  renal  problems,  and  does  not  affect  articular  cartilage.  However,  the  effect  
on  pain  is  small,  12.5  on  a  100mm  VAS,  which  represents  the  smallest  noticeable  change.  Apart  
IURPWUDGLWLRQDORSLRLGVLGHHIIHFWVWKHUHLVDULVNRIGHYHORSLQJD³VHURWRQLQV\QGURPH´LI
tramadol  is  combined  with  other  monoamine  oxidase  inhibitors.  The  most  frequent  clinical  fea-­
WXUHVZLWKLQWKLVV\QGURPHDUHFKDQJHVLQPHQWDOVWDWXVUHVWOHVVQHVVP\RFORQXVK\SHUUHÀH[LD





In  addition  to  being  a  weak  opioid  agonist  it  also  inhibits  the  neuronal  re-­uptake  of  serotonin  and  
norepinephrine.  Since  the  analgesic  effects  of  tramadol  are  not  fully  reversed  by  the  administra-­
WLRQRIQDOR[RQHPHFKDQLVPVRWKHUWKDQWKHDFWLRQRQWKHȝRSLRLGUHFHSWRUPXVWEHLQYROYHG
(92).  
Tramadol  is  structurally  similar  to  and  shares  some  of  its  mechanism  of  action  with  venlafaxine  
(93,  94).  Apart  from  monoaminergic  pathways  tramadol  as  well  as  venlafaxine  interact  with  the  
NMDA  receptors  (95)  and  inhibit  ion  channel  activity,  mechanisms  suggested  to  be  involved  in  
central  sensitization  (28).  Furthermore,  tramadol  has  been  shown  to  prevent  thermal  hind  paw  
hyperalgesia  in  the  rat  and  has  therefore  been  suggested  to  be  a  potential  agent  in  the  treatment  of  
neuropathic  pain  and  the  prevention  of  central  sensitization  (29).  
$OWKRXJKWKHDQDOJHVLFDFWLRQRIWUDPDGROLV\HWWREHIXOO\FODUL¿HGVHYHUDODFWLRQVRQUHFHSWRUV
in  the  central  nervous  system  have  been  demonstrated.  Thus,  tramadol  has  been  also  been  sug-­
gested  as  a  serotonin  releasing  agent,  norepinephrine  re-­uptake  inhibitor,  NMDA  receptor  antago-­
QLVW +7&UHFHSWRU DQWDJRQLVW Į  QLFRWLQLF DFHW\OFKROLQH UHFHSWRU DQWDJRQLVWV7539
receptor  agonist,  and  a  muscarinic  acetylcholine  receptor  antagonist  (96).  
  
Figure  4.  The  two  isomers  in  the  racemic  mixture  of  tramadol  
  
SURGICAL  TREATMENT  OF  OA
Arthroscopic  lavage  and  debridement
Arthroscopic  lavage  and  debridement  consists  of  shaving  rough  and  loose  areas  of  cartilage  and  





Repair  of  cartilage  defects  is  only  indicated  for  focal  defects.  The  different  techniques  are  divided  
into  bone  marrow  stimulation,  osteochondral  transplantation,  -­  and  chondrocyte  transplantation.  
Bone  marrow   stimulation   is   achieved   by   simply   penetrating   the,   often   sclerotic,   subchondral  
ERQHZKLFKVWLPXODWHVKHDOLQJZLWKPRVWO\¿EURXVWLVVXH,WLVZLGHO\XVHGEHFDXVHRILWVVLPSOLF-­




gous  chondrocyte  transplantation  was  introduced  by  Brittberg  and  colleagues  in  1994  (99).  This  
PHWKRGXWLOL]HVFXOWLYDWHGFKRQGURF\WHVWKDWDUHUHLPSODQWHGXQGHUQHDWKDSHULRVWHDOÀDS$OVR
this  technique  has  been  shown  to  decrease  symptoms  but  there  is  no  evidence  of  a  superior  effect  
compared  to  other  treatments  (100).
Osteotomies
In  relatively  young  active  patients  with  a  unicompartmental  OA  associated  with  a  varus  or  valgus  
malalignment  but  with  a  good  range  of  motion,  osteotomy  around  the  knee  is  an  alternative  to  
MRLQWUHSODFHPHQW7KHDLPLVWRDOWHUWKHPHFKDQLFDOD[LVDQGWKHUHE\XQORDGWKHRVWHRDUWKULWLF
compartment.  By  pre-­  and  postoperative  gait  analysis  it  has  been  shown  that  the  load  is  reduced  
QRWRQO\LQWKHNQHHEXWDOVRLQWKHKLSMRLQWDIWHURVWHRWRP\2OGHUWHFKQLTXHVDVWKHFORVLQJ
wedge  osteotomy  were  associated  with  a  risk  of  damage  to  the  peroneal  nerve  or  shifting  of  the  




1940’s.  In  1953  Walldius,  a  Swedish  orthopaedic  surgeon  published  some  promising  results  with  
a  hinge  prosthesis  made  of  acrylate  (103).  In  the  1970’s  the  concept  of  replacing  the  tibiofemoral  
FRQG\ODUVXUIDFHVZLWKFHPHQWHG¿[DWLRQZDVSRSXODUL]HG$IWHUELRPHFKDQLFDOVWXGLHVE\*XQ-­
ston  in  1971  (104),  recognizing  that  the  femoral  condyles  not  only  roll  but  also  glide  on  the  tibia,  
the  total  condylar  knee,  based  on  the  principle  of  a  low  friction  arthroplasty  was  developed  by  
Insall  (105).  Arthroplasty  is  currently  performed  by  replacement  of  one,  two,  or  all  three  compart-­
ments  of  the  knee,  i.e.  the  lateral,  medial,  and  patello-­femoral  compartments.  TKA  is  the  most  
effective  treatment  for  patients  with  advanced  OA  (106).  In  a  study  on  the  long-­term  results  of  
TKA,  pain  relief  was  found  to  remain  20  years  or  more  after  surgery  (107).  The  indications  for  
7.$YDU\EHWZHHQVXUJHRQV3DLQLVJHQHUDOO\DFFHSWHGDVWKHPDMRUFULWHULRQ%XWDFFRUGLQJ
to  a  study  by  Mancuso  from  1996  (108)  most  surgeons  in  New  York  City  would  require  severe  
pain  and  transfer  pain  at  least  daily  and  rest  pain  at  least  several  days/week  before  performing  a  
TKA.  
Figure  5.  Radiograph  of  a  patient  with  predominantly  medial  osteoarthritis  in  the  right







only  a  cause  of  discomfort  and  unnecessary  suffering  for  the  patient,  but  severe  postoperative  
pain  can  also  delay  mobilization  with  an  increased  risk  of   thromboembolism,   lengthening  the  
patient’s  hospital  stay.  Acute  postoperative  pain  has  also  been  implicated  as  a  risk  factor  for  per-­
sistent  postsurgical  pain  (109).  Despite  the  awareness  of  the  consequences  of  acute  postsurgical  
pain,  it  is  not  seldom  poorly  managed  (110).
Persistent  postsurgical  pain  
In  the  literature  chronic-­  and  persistent  postsurgical  pain  are  two  terms  used  interchangeably  to  
describe  a  clinical  picture  of  pain  still  occurring  three  months  after  surgical  intervention  (111).  We  
KDYHFKRVHQWKHWHUP³SHUVLVWHQW´DV³FKURQLF´LQRXURSLQLRQGHQRWHVDQLUUHYHUVLEOHFRQGLWLRQ
Persistent   postsurgical   pain   is   an   under-­recognized   problem   affecting   10   to   50  %  of   surgical  
patients(109).  After   total  knee  arthroplasty   (TKA),  44%  of  patients   report  persistent  pain  and  
RIWKHVHKDYHVHYHUHWRH[WUHPHSDLQ$QXPEHURIULVNIDFWRUVKDYHEHHQLGHQWL¿HG
These  include  female  gender,  low  age,  intensity  of  preoperative  pain  (19)  and  acute  postoperative  
pain,  psychic  vulnerability,  anxiety  and  a  surgical  approach  causing  nerve  damage  (109).
6XUJHU\ HOLFLWV DQ DFXWH LQÀDPPDWRU\ UHVSRQVHZLWK WKH UHOHDVHRI SURVWDJODQGLQV DQG F\WRN-­
ines,  which  activate  and  sensitize  primary  afferents,  which  in  turn  promotes  central  sensitization.  
These  sensitization  mechanisms  are  adaptive  in  the  sense  that  they  protect  the  body  from  further  
damage.  However,  some  patients  experience  pain  which  persists  for  months  or  even  years  after  
surgical  intervention.  Persistent  pain  after  surgery  is  likely  to  result  from  a  complex  combination  
of  mechanisms.  
PREVENTIVE  ANALGESIA
Pre-­emptive  and  preventive  analgesia  have  been  developed  to  inhibit  the  mechanisms  leading  to  
persistent  postsurgical  pain  (113,  114).  Early  experimental  observations  demonstrated  that  anal-­
JHVLFVDSSOLHGEHIRUHLQMXU\ZDVPRUHHIIHFWLYHLQUHGXFLQJFHQWUDOVHQVLWL]DWLRQWKDQSRVWLQMXU\
administration.  Pre-­emptive  analgesia  is  believed  to  minimize  the  risk  of  acute  and  chronic  pain  
by   reducing  afferent  nociceptive   transmission  provoked  by   the  procedure  whereas  preventive  
analgesia  is  based  on  the  assumption  that  the  only  way  to  prevent  central  sensitization  is  to  com-­
pletely  block  pain  and  afferent  signals  from  the  surgical  wound  at  the  time  of  incision  until  wound  
KHDOLQJ,QWKHPDMRULW\RIUHFHQWVWXGLHVSUHHPSWLYHDQDOJHVLFVVKRZHGQREHQH¿WRYHUSUHYHQ-­
tive  analgesia  and  it  has  been  suggested  that  the  term  pre-­emptive  analgesia  should  be  abandoned  
in  favour  of  preventive  analgesia.  
Among  agents  with  a  potential  to  prevent  central  neuroplasticity  leading  to  sensitization  prom-­
ising   results   have   been   found  with   perioperative   administration   of   ketamin,   celecoxib   (115),  
venlafaxine(116),  gabapentin  (117),  and  pregabalin  (118).  Although  tramadol  is  often  considered  
to  be  an  opioid,  the  opioid  properties  of  tramadol  seem  to  be  very  limited.  Tramadol  shares  its  
25
mechanism  of  action  with  venlafaxine  by  inhibiting  the  neuronal  re-­uptake  of  serotonin  and  nor-­
epinephrine  (93).Tramadol  given  perioperatively  may  therefore  have  a  potential  for  preventing  
persistent  postsurgical  pain.  TKA  is  a  standardized  surgical  procedure  that  seemingly  would  be  









t The  origin  and  mediation  of  pain  at  rest  and  pain  with  movement  differ.  The  two  pain  
modalities  should  therefore  be  assessed  separately
t Pain  with  movement  is  predominantly  related  to  grade  of  radiographic  OA  whereas  pain  
DWUHVWSUHGRPLQDQWO\LVUHODWHGWRJUDGHRILQÀDPPDWLRQ
t Central  sensitization  is  a  contributing  factor  to  pain  in  chronic  OA  pain  as  well  as  in  un-­
explained  persistent  pain  after  TKA
t Pain  thresholds  to  electrical  stimulation  can  be  used  to  identify  patients  at  increased  risk  
of  persistent  pain  after  TKA
t Tramadol  mitigates  acute  postoperative  pain
t Tramadol  has  a  preventive  effect  on  persistent  pain  after  TKA  
Aims
t To  test  whether  separate  assessment  of  pain  at  rest  and  pain  with  movement  preopera-­
tively  is  useful  for  predicting  pain  relief  by  TKA
t 7RWHVWZKHWKHUSDLQDWUHVWDQGSDLQZLWKPRYHPHQWLQ2$GLIIHULQWHUPVRILQÀDPPD-­
tory  or  radiographic  changes  
t To  assess   the  value  of  preoperative  grade  of   radiographic   and  histological   changes   in  
prediction  of  pain  relief  by  TKA
t To  establish  the  usefulness  of  the  Pain  Matcher®  as  a  tool  for  measurement  of  pain  in  OA  
and  prediction  of  pain  relief  by  TKA
t To  test  if  the  risk  of  persistent  pain  18  months  after  TKA  is  related  to  the  intensity  of  acute  
postoperative  pain
t To  determine  whether  intravenous  tramadol  100  mg  x  4  as  add-­on  to  morphine  adminis-­
tered  via  a  PCA  pump  results  in  better  pain  relief  after  TKA  than  morphine  alone
t To  test  whether  tramadol  administered  for  24  hours  after  surgery  prevents  persistent  pain  






The  study  was  approved  by  the  local  ethics  committee  and  conducted  in  accordance  with  the  Dec-­
laration  of  Helsinki  and  Good  Clinical  Practice.  All  patients  provided  written  informed  consent  
prior  to  participation.  
PARTICIPANTS
Men  and  women  aged  18–80  years,  with  American  Society  of  Anaesthesiologists  (ASA)  physi-­
cal  status  I  or  II  and  primary  osteoarthritis,  selected  for  elective  TKA  with  spinal  anaesthesia  at  
Stockholm  Spine  Centre,  were  enrolled  between  February  2002  and  August  2004.  The  exclusion  
criteria  were  as  follows:  creatinine  level  above  160  mmol/l;;  intolerance  to  tramadol  or  morphine;;  
seizures  or  cardiac  arrhythmias;;  or  communication  problems.  Distribution  of  the  75  patients  re-­
cruited  for  participation  and  reasons  for  exclusion,  withdrawal,  or  discontinuation  are  presented  
LQWKHÀRZFKDUWLQ)LJXUH7KHSRSXODWLRQVµLQWHQWLRQWRWUHDW¶RUµSHUSURWRFRO¶XVHGIRUVWD-­
tistical  calculations  are  also  given.  Because  of  administrative  failures  or  consent  withdrawals  10  
patients  in  paper  II  and  4  patients  in  paper  III  and  I  were  excluded.  The  number  of  patients  ex-­
cluded  in  the  different  studies  (paper  I-­IV)  varied  because  of  differences  in  protocols  and  consent  
withdrawals.  
3UHRSHUDWLYHSDWLHQWFKDUDFWHULVWLFVDUHVKRZQLQ7DEOH1RVLJQL¿FDQWGLIIHUHQFHVEHVLGHVVPRN-­
ing  habits  were  found  between  groups.  
Table  1  Baseline  characteristics  of  the  patients  
          
Characteristic
Paper  I  and  III  
(n=  69)
Randomized  in  paper  II  (n=63)  
Tramadol  n=32              Placebo  n=31
Age  in  years M  (SD) 68  (8.1) 68  (8.6) 68  (8.7)
Weight  in  kg M  (SD) 84  (15.5) 81  (17.0) 86  (13.9)
BMI M  (SD) 30  (5.0) 30  (4.8) 29  (5.2)
Duration  of  knee            
pain  in  years
M  (SD) 8.5  (6.2) 9.8  (7.6) 7.8  (5.6)
Smoking  habits   Yes  (%) 12  (17) 3  (9) 8  (26)








        
  
  
Figure  3.  Flow  chart  showing  the  reasons  for  withdrawal  and  explanation  of  the  patient  study  groups  used  
for  statistical  analysis.  

















































9Withdrawal or  
administrative reasons (n=4) 
9Spinal morphine (n=2) 
Excluded (n=12) 
9Withdrawal or  
administrative reasons (n=10) 
9Spinal morphine (n=2) 
Paper I and III 
Paper II 
Radiographs graded 
according to Ahlbäck 
and Kellgren-Lawrence 
(n=65) 
Allocated to tramadol 
(n=31) 
Intention to treat (ITT) 
Allocated to placebo 
(n=32) 
Intention to treat (ITT) 
Histological evaluation 
Grade of inflammation 
(n=67) 
Radiographs lost due to 
fire in archive (n=4) 
No synovial membrane 
in the biopsy (n=2) 
TKA in spinal anaesthesia 
Received 1st dose of tramadol 
                   (n=31) 
Received 1st dose of placebo  





Continued to receive  
Dose 2-4 (n=24) 
Continued to receive  





Anxiety and confusion 
(n=1) Withdrawn  
Atrial fibrillation 
(n=1) 
Completed Study:  
Dose 1-4 (n=28) 
Per protocol (PP) 
18 months after TKA 
Analysis of pain at rest (n=63) 
Pain with movement (n=62) 
Completed Study:  
Dose 1-4 (n=22) 
Per protocol (PP) 
Completed Study II: 
n=50  
Per protocol (PP) 
 
Completed study I-III 
Analysis of pain at rest (n=49) 




Preoperative  pain  according  to  VAS
All  patients  were  interviewed  the  day  before  surgery  about  the  total  duration  of  knee  pain  and  
WKHFXUUHQWLQWHQVLW\RISDLQDWUHVWDQGZLWKPRYHPHQW7KHODWWHUZDVGH¿QHGDVSDLQGXULQJ
walking.  Preoperative  pain  intensity  was  assessed  using  the  visual  analogue  scale,  VAS  (Figure  
2),  (59).  The  use  and  validity  of  VAS  for  pain  assessment  have  been  reported  previously  (58,  59,  
119).  The  ratings  were  recorded  on  a  scale  with  the  endpoints  0  and  10  on  a  100  mm  horizontal  
line.  Patients  moved  a  vertical  line  along  the  horizontal  scale  and  selected  a  position  that  corre-­
sponded  to  the  intensity  of  pain.  The  left  endpoint  represents  no  pain  whereas  the  right  endpoint  
depicts  the  worst  imaginable  pain.  The  ratings  on  the  back  of  the  scale  were  read  and  recorded  as  
whole  numbers  (0-­10).  The  rationale  for  recording  ratings  on  the  VAS  as  whole  numbers  was  that  
this  is  the  way  the  scale  is  used  in  clinical  practice.  In  paper  IV  the  preoperative  pain  ratings  were  
transformed  to  a  scale  between  0  and  100  to  enable  comparison  with  the  pain  ratings  during  the  
¿UVWSRVWRSHUDWLYHGD\UHSRUWHGLQSDSHU,,
Pain  Matcher®
The  Pain  Matcher   (PM),  Figure  3,  is  an  instrument  for  electrical  stimulation  that  was  developed  
for  assessing  the  magnitude  of  pain  (62,  120).  The  patient  matches  perceived  pain  in  a  certain  
UHJLRQRIWKHERG\WRDSK\VLFDOVHQVDWLRQEHWZHHQWKHWKXPEDQGLQGH[¿QJHUSURGXFHGE\WKH
PM  (121).  The  Pain  Matcher®     provides  constant  current  stimulation,  despite  variable  skin  re-­
sistance,  and  is  controlled  by  a  microprocessor,  which  provides  rectangular  pulses  at  a  frequency  
of  10  Hz  and  amplitude  of  10  mA.  Increasing  the  stimulus  is  done  by  gradually  raising  the  pulse  
ZLGWKIURP]HURWRDSRVVLEOHPD[LPXPRIȝVLQLQFUHPHQWVRIȝVRYHUDWRWDORIVWHSV
The  electrical  current  is  extremely  low  and  causes  no  tissue  damage.  The  value  reached  (0  to  99)  
is  directly  related  to  the  pulse  width  and  is  displayed  on  a  liquid  crystal  screen.  Measuring  pain  
with  the  PM  has  been  shown  to  be  reliable  (122,  123).  We  used  the  PM  preoperatively  on  all  pa-­
tients  to  assess  not  only  the  matched  pain,  i.e.,  the  pain  corresponding  to  the  knee  pain  with  move-­
ment,  but  also  to  determine  sensory  and  pain  threshold  to  the  electrical  stimulus.  As  a  control  
group,  12  men  and  12  women,  all  healthy  and  without  pain,  were  tested  for  the  same  thresholds.    
Radiographic  grade  of  OA
Anterior-­posterior  and  lateral  radiographs  were  taken  with  equal  weight  bearing  on  both  legs  in  
RIÀH[LRQRULQWKHFDVHRIFRQWUDFWXUHDWPD[LPDOH[WHQVLRQ$OOUDGLRJUDSKVZHUHUHDGE\DQ










Grade  I Joint  space  narrowing  (joint  space  <  3  mm)
Grade  II Joint  space  obliteration
Grade  III Minor  bone  attrition  (0–5  mm)
Grade  IV Moderate  bone  attrition  (5–15  mm)
Grade  V Severe  bone  attrition  (>15  mm)
  
Table  2b  7KH.HOOJUHQ	/DZUHQFHFODVVL¿FDWLRQV\VWHPRIUDGLRJUDSKLFNQHH2$
Kellgren  &  Lawrence  grade .HOOJUHQ	/DZUHQFHGH¿QLWLRQ
Grade  1  ‘Doubtful’ 0LQXWHRVWHRSK\WHGRXEWIXOVLJQL¿FDQFH
Grade  2  ‘Minimal’ 'H¿QLWHRVWHRSK\WHXQLPSDLUHGMRLQWVSDFH
Grade  3  ‘Moderate’ Moderate  diminution  of  joint  space,  with  osteophytes
Grade  4  ‘Severe’ Joint  space  greatly  impaired  with  sclerosis  of  subchondral  bone
RANDOMISATION  
The  study  presented  in  paper  II  was  a  single-­centre,  parallel,  double-­blind,  randomized  trial  with  
two  treatment  groups:  (i)  tramadol  100  mg  in  100  ml  physiological  saline  solution  for  intrave-­
QRXVLQIXVLRQDGPLQLVWHUHGIRXUWLPHVHYHU\KGXULQJWKH¿UVWSRVWRSHUDWLYHGD\LLPO
SK\VLRORJLFDOVDOLQHVROXWLRQDGPLQLVWHUHGIRXUWLPHVHYHU\KGXULQJWKH¿UVWSRVWRSHUDWLYH
day.  The  Pharmacy  of   the  Karolinska  University  Hospital   (Karolinska  Apoteket,  Solna,  Swe-­
den)  received  the  name  and  date  of  birth  of  the  included  patient  and  prepared  four  100-­ml  bags  
containing  saline  solution  with  or  without  tramadol;;  the  infusion  bags  were  identical  except  for  
the  label  with  the  patient’s  name  and  birth  date.  A  manually  generated  Randomisation  list  with  
blocks  of  six,  based  on  a  Randomisation  table  according  to  the  Quality  Manual  of  Apoteket  AB,  
Chapter  10  (Pharmacist  Gudrun  Ekberg),  was  used.  The  four  infusion  bags  were  available  after  
termination  of  surgery.  
SURGICAL  PROCEDURE
Surgery  was  performed  in  spinal  anaesthesia  at  the  Karolinska  Hospital  according  to  our  standard  
procedure  using  the  PFC   Sigma  knee  prosthesis  (Johnson  &  Johnson).  The  femoral  component  
was  positioned  using  an  intra-­medullar  guide.  Rotational  alignment  was  achieved  using  the  pos-­
terior  condyles  as  reference.  In  cases  with  a  valgus  knee  or  uneven  cartilage  erosion  Whiteside’s  
line  and  the  epicondyles  were  considered  for  the  same  purpose.  The  tibial  component  was  po-­
sitioned  with  an  extra-­medullar  guide.  Rotational  alignment  was  determined  with   the  patellar  
WHQGRQDVDUHIHUHQFHDQGE\WHVWLQJSDWHOODUWUDFNLQJGXULQJÀH[LRQDQGH[WHQVLRQ7KHSDWHOOD
was  not  resurfaced  in  any  case.  
During  surgery  two  samples  were  taken  from  the  synovial  membrane.  One  full  thickness  (syn-­
RYLDOPHPEUDQHDQG¿EURXVFDSVXOHELRSV\RIDSSUR[LPDWHO\[PPZDVWDNHQIURPWKH
synovial  fold  above  the  femoral  cartilage  shield.  The  other  biopsy  entailed  an  isolated  sample  
RIV\QRYLDOPHPEUDQHIURPWKHVLWHRIPRVWSURQRXQFHGLQÀDPPDWLRQLHYLVLEOHVZHOOLQJDQG
redness.  All  samples  were  immediately  frozen  to  -­58º  C.  After  one  week  the  samples  were  trans-­
ferred  to  -­70º  C  and  kept  there  until  analysis.
33
PROTOCOL
Following  surgery,  when  pain  intensity  had  reached  40  mm  on  the  VAS,  patients  received  a  PCA-­
SXPSIRULQWUDYHQRXVDGPLQLVWUDWLRQRIPRUSKLQHPJPODVZHOODVWKH¿UVWGRVHRIVWXG\
medication  (saline  or  tramadol  100  mg).  On  patient  request,  1-­2  mg  of  morphine  was  delivered  
each  time  the  PCA  pump  was  activated.  All  patients  had  the  option  to  receive  additional  morphine  
from  the  study  nurse.  The  administration  of  the  study  drugs  was  repeated  every  6  hours.  In  order  











patients  were  informed  to  report  any  side  effects  they  encountered.
+LVWRORJLFDOJUDGHRILQÀDPPDWLRQ
Synovial  tissue  from  all  patients  were  sectioned  at  10µm  using  a  Microm  HM  560  cryostat.  The  
sections  were  mounted  directly  on  SuperFrost/Plus  glass  slides  and  stained  with  Hematoxylin-­







Synovial  lining  4  or  5  cells  thick,  increased  cellularity  with  some  
LQÀDPPDWRU\FHOOV
1 0LOGLQÀDPPDWLRQ 6\QRYLDOOLQLQJRUFHOOVWKLFNGHQVHFHOOXODULW\ZLWKLQÀDP-­
matory  cells  but  not  lymphoid  aggregates
2 0RGHUDWHLQÀDPPDWLRQ 6\QRYLDOOLQLQJRUFHOOVWKLFNGHQVHFHOOXODULW\ZLWKLQÀDP-­






Pain  18  months  after  TKA
At  18  months  postoperatively  a  questionnaire  was  sent  to  all  patients,  who  were  asked  to  estimate  
pain  intensity  at  rest  and  with  movement  according  to  the  VAS  as  done  before  surgery.  Instead  of  
merely  calculating  mean  postoperative  pain  for  the  entire  group,  pain  relief  was  assessed  for  each  
patient  individually,  after  which  the  mean  pain  relief  was  determined  for  the  entire  group.  Since  
the  change  in  VAS  from  pre-­  to  postoperative,  delta  pain,  depends  on  the  magnitude  of  preopera-­





percent  using  a  two-­tailed  test.  All  variables  were  summarized  using  standard  descriptive  statis-­
tics  such  as  mean,  standard  deviation  (SD),  and  frequency.  Due  to  skewed  distributions  correla-­
WLRQVZHUHFDOFXODWHGDV.HQGDOO¶VUDQNRUGHUFRUUHODWLRQFRHI¿FLHQWVĲ7KHSUHGLFWLYHYDOXHRI
preoperative  measurements  was  evaluated  with  a  logistic  regression  analysis  (stepwise  forward).  
The  inclusion  criterion  was  5  percent.  The  logistic  regression  analysis  yields  the  relationships  as  
RGGVUDWLRVZLWKDSHUFHQWFRQ¿GHQFHLQWHUYDO$OOYDULDEOHVHQWHUHGLQWKHORJLVWLFUHJUHVVLRQ
ZHUHGLFKRWRPL]HG7KHVLJQL¿FDQFHOHYHOZDVSHUFHQWWZRWDLOHG
For  paper  II  the  size  of  the  trial,  i.e.  the  number  of  patients  included,  was  based  on  the  clinical  
assumption  that  a  difference  of  17  mm  in  mean  VAS  between  the  two  treatment  groups  during  
WKH¿UVWSRVWRSHUDWLYHGD\VKRXOGEHFOLQLFDOO\VLJQL¿FDQW7KHSRZHUDQDO\VLVZDVEDVHGRQD
standard  deviation  of  the  pain  intensity  of  20  mm,  as  reported  in  a  similar  patient  sample  (125).  
$VDPSOHVL]HRILQHDFKJURXSVKRXOGEHVXI¿FLHQWWRGHWHFWDGHFUHDVHLQSDLQLQWHQVLW\RI
ZLWKSRZHUDQGD»XVLQJWKHXQSDLUHG6WXGHQW¶VWWHVW*UDSK3DG6WDW0DWH
GraphPad,  San  Diego,  CA).  Differences  in  pain  intensity,  sedation,  nausea,  and  morphine  con-­




The  mean  values  of  the  preoperative  characteristics  are  similar  to  other  reports  on  patients  with  
knee  OA  scheduled  for  TKA  (126).  After  a  mean  period  of  8.5  years  with  gradually  increasing  
stiffness  and  pain  in  the  affected  knee,  the  patient  was  referred  to  an  orthopaedic  surgeon.  Nota-­
bly,  the  main  complaint  and  the  reason  for  consultation  was  pain  with  movement.  Radiological  
examination  typically  revealed  a  medial  compartmental  osteoarthritis  with  a  slight  varus  defor-­
mity.  A  few  patients  (17%)  reported  moderate  to  severe  pain  also  at  rest.  
VAS  
3UHRSHUDWLYHSDLQUDWLQJVDUHVKRZQLQ7DEOH1RVLJQL¿FDQWJHQGHUGLIIHUHQFHLQWKHSDLQUDW-­
ings  according  to  VAS  was  found.  As  mentioned  above,  the  main  complaint  of  patients  scheduled  
for  TKA  because  of  OA  was  pain  with  movement.  Almost  25  percent  (16/69)  of  the  patients  had  
QRSDLQDWUHVW3DLQDWUHVWZDVVLJQL¿FDQWO\OHVVLQWHQVHWKDQWKDWZLWKPRYHPHQW] S
0.001).  Out  of  69  patients,  65  (94%)  scored  5  or  higher  for  pain  with  movement  (VAS  0-­10),  but  
only  12  (17%)  scored  5  or  higher  for  pain  at  rest  (VAS  0-­10).  
We   found  no  correlation  between   the   intensity  of  pain   at   rest   and  pain  with  movement.  This  
is  an  interesting  observation.  The  sources  of  pain  in  OA  are  not  fully  understood,  but  it  can  be  
speculated  that  pain  at  rest  is  caused  by  a  different  mechanism  than  pain  with  movement.  The  
sensory  qualities  of  pain  at  rest  in  knee  OA  are  often  described  as  aching,  tiring,  and  tenderness  
indicating  an  underlying  neuropathic  component.  Pain  with  movement  on  the  other  hand  is  more  
often  described  as  sharp,  which  indicates  nociceptive  pain  mediated  by  A-­δ¿EUHV.  A  distinction  
EHWZHHQSDLQDWUHVWDQGSDLQZLWKPRYHPHQWLVRIFOLQLFDOVLJQL¿FDQFH,WPD\SURYHWKDWWKHVH
two  modalities  of  pain  in  OA  represent  activation  of  different  nerve  terminals  that  have  altered  
thresholds.  
7DEOH  Mean  preoperative  pain  ratings  in  the  69  patients
Variable Mean SD Range
Visual  analogue  scale
Pain,  at  rest 2.4 1.86 0  to  7
Pain,  with  movement 7.1 1.72 3  to  10
Pain  Matcher®  
Sensory  threshold 7.1 3.17 3  to  19
Pain  threshold 16.4 10.63 5  to  78




Quantitative  Sensory  Testing  (QST)  -­  Pain  Matcher®  
Mean  preoperative  values  of  matched  pain,  pain  and  sensory  thresholds  are  shown  in  Table  4.  As  
in  previous  studies  (127),  the  patient  group  compared  to  the  normal  reference  group,  exhibited  a  
VLJQL¿FDQWO\KLJKHUVHQVRU\WKUHVKROGYVDQGDVLJQL¿FDQWO\ORZHUSDLQWKUHVKROG
vs.  21.1).  On  average  the  pain  threshold  was  2.4  (range  1.1-­9.6)  times  higher  than  the  sensory  
threshold.  The  matched  pain  on  motion  was  1.42   times  higher   than   the  pain   threshold   (range  
)XUWKHUPRUHZRPHQKDGVLJQL¿FDQWO\ORZHUVHQVRU\WKUHVKROGVWKDQPHQYV
] S DQGDOVRORZHUSDLQWKUHVKROGVYV] S 7KHPDWFKHG
SDLQRQPRWLRQKRZHYHUZDVVLJQL¿FDQWO\ORZHUWKDQWKDWIRUPHQYV] S 
0.001).
The  tool  used  in  the  present  study  for  matching  of  pain  and  determining  sensory  thresholds  and  
pain  threshold,  i.e.,  Pain  Matcher®,  has  been  reported  to  be  both  reliable  and  reproducible  (62).  
+RZHYHULQWKLVVWXG\ZHIRXQGLWGLI¿FXOWIRUSDWLHQWVWRPDWFKWKHSDLQLQÀLFWHGE\WKH3DLQ
Matcher®  to  knee  pain.  As  in  previous  studies  (121)  some  patients  found  the  electrical  impulse  
unpleasant  and  therefore  stopped  the  test  before  experiencing  pain.  Others  had  problems  in  dis-­
FULPLQDWLQJSDLQIURPXQSOHDVDQWQHVV7KHGLI¿FXOWLHVLQXQGHUVWDQGLQJWKHLQVWUXFWLRQVZDVUH-­
ÀHFWHGE\DVPDQ\DVRISDWLHQWVVFRULQJKLJKHUIRUSDLQWKUHVKROGWKDQIRUPDWFKHGSDLQGH-­
spite  reporting  considerable  knee  pain  on  the  VAS  scale.    Also  the  discordance  between  matched  
DQGVFRUHGMRLQWSDLQLQGLFDWHVWKDW³PDWFKHGSDLQ´DVGHWHUPLQHGE\3DLQ0DWFKHULVRITXHV-­
tionable  value.  Nonetheless,  our  data  suggests  that  the  tool  can  offer  meaningful  measurements  
of  thresholds  for  sensation  and  pain.
  
$ORZSDLQWKUHVKROGWRDQHOHFWULFDOVWLPXOXVWRDVLWHGLVWDQWIURPWKHDUWKULWLFMRLQWKDVEHHQDV-­
sociated  with  a  central  sensitization.  The  low  thresholds  to  pain  in  patients  with  OA  compared  to  
healthy  controls  therefore  may  indicate  a  central  sensitization  as  a  contributing  factor  to  pain  in  
long  standing  OA.
Radiographic  changes
The  average  grade  of   radiographic  OA  as  well  as   the  distribution  of  patients   in  each  grade   is  
shown  in  Table  5a-­b.  Most  patients  presented  with  predominantly  medial  compartmental  osteoar-­
thritis.  Seven  patients  (10%)  had  a  lateral  compartmental  OA  and  out  of  65  patients  evaluated  
for  radiographic  OA  61  had  signs  of  patello-­femoral  OA  of  any  degree  according  to  the  Ahlbäck  
scale  and  26  patients  according  to  the  Kellgren  &  Lawrence  scale.  Although  criticism  exists  of  
both  scales  they  are  extensively  used  and  intra-­observer  reliability  has  been  found  to  be  accept-­
able,  albeit  dependent  on  experienced  radiologists  (73,  74).  In  order  to  obtain  data  that  are  ap-­





7DEOHD  Mean  preoperative  grade  of  radiographic  OA
Variable n Mean SD Range
Worst  compartment  OA
Ahlbäck 65 3.4 0.76 1-­4
Kellgren  &  Lawrence 65 3.5 0.64 2-­4
Patello-­femoral  OA
Ahlbäck 65 1.22 0.42 0-­4
Kellgren  &  Lawrence 65 0.66 0.88 0-­4
  
7DEOHE  Number  of  patients  according  to  grade  of  morphological  changes
Worst  compartment  OA Patello-­femoral  OA Histological  OA
Grade Ahlbäck K  &  L Ahlbäck K  &  L n
0 0 0 4 39 36
1 1 0 45 12 22
2 8 5 13 12 6
3 22 21 1 1 3
4 34 39 1 1 -­
5 0 -­ 0 -­ -­













Radiographic  studies  focusing  on  individual  features  of  OA,  e.g.  osteophytes,  subchondral  bone  
VFOHURVLV V\QRYLDO WKLFNHQLQJPHQLVFDO WHDUVHWFKDYH UHSRUWHGVLJQL¿FDQWDVVRFLDWLRQVZLWK
pain  (128).  In  a  recent  population  based  study  using  a  global  Kellgren  &  Lawrence  score  Neogi  
et  al.  (25)  found  a  strong  association  between  pain  and  radiographic  OA.  In  the  present  study  the  
failure  to  demonstrate  a  similar  relationship  may  be  explained  by  the  selection  of  patients  with  
KLJKSDLQVFRUHVW\SLFDOIRUWKRVHUHTXLULQJVXUJLFDOLQWHUYHQWLRQ)LQGLQJDVLJQL¿FDQWUHODWLRQ-­
ship  between  pain  scores  among  patients  selected  for  TKA  and  other  variables  is  obviously  more  




VAS  scale.  However,  the  discordance  between  pain  and  grade  of  radiographic  OA  is  probably  
explained  by  the  heterogeneity  of  patients  with  OA.  This  is  manifested  by  different  grade  of  e.g.  
central  and  peripheral  sensitization,  synovitis  and  intraosseous  pressure,  or  simply  in  different  
personal  interpretations  of  pain.      
7DEOH  Correlations  between  pain  and  morphological  features  of  OA
Variable 2 3 4 5
VAS
1 Pain  at  rest 0.10 -­0.09 -­0.09 0.11
2 Pain  with  movement -­ 0.16 0.05 -­0.17
Radiographic  grade
3 Kellgren  &  Lawrence -­           0.74*** 0.01




$V VKRZQ LQ7DEOH  WKHUHZDV QR VLJQL¿FDQW FRUUHODWLRQ EHWZHHQ WKH JUDGH RI UDGLRJUDSKLF
FKDQJHVDQGWKHKLVWRORJLFDOJUDGHRILQÀDPPDWLRQZKLFKDOVRKDVEHHQVXJJHVWHGDVDVRXUFH
RISDLQLQ2$+RZHYHUHIIRUWVWR¿QGDUHODWLRQEHWZHHQSDLQDQGLQÀDPPDWRU\FKDQJHVLQ2$
have  been  contradictory  (36,  38,  129).  We  noted  a  tendency  for  patients  with  histological  signs  
RILQÀDPPDWLRQWRUHSRUWDKLJKHUVFRUHIRUSDLQDWUHVW,QWKHHQWLUHJURXSRXWRI
SDWLHQWVUHSRUWHGSDLQDWUHVWSULRUWRVXUJHU\$PRQJWKHSDWLHQWVZLWKLQÀDPPDWRU\FKDQJHV
in  the  synovial  membrane,  as  many  as  26  (87  %)  had  pain  at  rest.  However,  as  shown  in  Table  6  
WKLVUHODWLRQZDVQRWVLJQL¿FDQW1HLWKHUGLGZH¿QGDQ\RWKHUVLJQL¿FDQWUHODWLRQVKLSVEHWZHHQ
morphological  features  and  the  preoperative  pain  ratings.  
It  was  expected  that  patients  with  a  low  pain  threshold  would  report  a  higher  preoperative  VAS  
score  for  pain  intensity  either  at  rest  or  with  movement.  It  was  also  speculated  that  patients  with  
V\QRYLWLVZRXOGKDYHORZHUWKUHVKROGVIRUSDLQVLQFHLQÀDPPDWLRQKDVEHHQVKRZQWRLQGXFHQRW
only  peripheral  but  also  central  sensitization  (5,  28).  However,  the  mean  values  of  sensory  and  
SDLQWKUHVKROGVDQGPDWFKHGSDLQZLWKPRYHPHQWZHUHQRWVLJQL¿FDQWO\UHODWHGWRWKHJUDGHRI
UDGLRORJLFDO2$RUKLVWRORJLFDOVLJQVRI LQÀDPPDWLRQ1RUZHUHWKHVHPRUSKRORJLFDOIHDWXUHV




pain  thresholds  on  one  hand  and  the  matched  pain  on  motion  on  the  other.  A  low  sensory  thresh-­
old  tended  to  be  associated  with  a  low  pain  threshold.
It  has  been  proposed  that  a  pain  threshold/sensory  threshold  of  less  than  2.0  suggests  an  altered  
central  nervous  system  processing  (66).  Pain  thresholds  to  electrical  stimulation  have  been  used  
in  the  detection  of  central  sensitization  (130).  As  signs  of  central  sensitization  have  been  demon-­
strated  among  non-­operated  patients  with  osteoarthritis  (5)  and  treatment  of  neuropathic  pain  has  
been  shown  to  be  effective  in  OA  (88)  it  appears  that  patients  with  OA  to  a  various  extent  may  be  
sensitized  even  before  TKA.
39
7DEOH  Relationships  between  different  aspects  of  pain  and  sensory  characteristics  as  deter-­
mined  by  the  visual  analogue  scale  (VAS)  and  Pain  Matcher  (Kendall’s  rank  order  correlation  
FRHI¿FLHQWV
Variable 2 3 4 5
Visual  analogue  scale  (VAS)
1. Pain  at  rest 0.10 -­0.08 -­0.04 0.05
2. Pain  with  movement -­ -­0.06 -­0.13 -­0.08
Pain  Matcher
3. Sensation  threshold -­ 0.42*** 0.46***
4. Pain  threshold -­ 0.52***
5. Matched  pain  –  with  movement -­
***  p<  0.001
THE  EFFECT  OF  TRAMADOL  ON  ACUTE  POSTOPERATIVE  PAIN  AND  
MORPHINE  CONSUMPTION
7KHDLPLQSDSHU,,ZDVWR¿QGHYLGHQFHIRUWKHHI¿FDF\RIFRPELQLQJWUDPDGRODQGPRUSKLQHE\
PCA  for  pain  relief  after  orthopaedic  surgery.  This  combination  was  used  in  our  practice  and  con-­
sidered  to  offer  better  pain  relief  and  fewer  side  effects  after  orthopaedic  surgery  than  morphine  
alone.  There  was  however  no  evidence  in  the  literature  for  this  combination.  
The  combination  of  tramadol  at  the  recommended  dose  of  100  mg  x  4  with  morphine  by  patient  
controlled  analgesia  (PCA)  did  not  result  in  superior  pain  reduction  after  TKA  (Figure  5).  Al-­
though  the  morphine  consumption  during  24  h  after  TKA  was  30%  lower  in  the  tramadol  group  






throughout  the  study  period  after  the  administration  of  one  to  four  doses  of  tramadol  100  mg  (‘intention  




7DEOH  Intention  to  treat  outcome  of  one  to  four  doses  of  tramadol  (100  mg)  administered  at    
6-­h  intervals  (24  h).
Placebo Tramadol
Group  size 32 31
Pain  VAS  primary  outcome 54  (50–59) 59  (51–67)
Nausea  VAS 3  (1–6) 6  (3-­9)
Sleep  rate  (%) 35 33
Withdrawal  rate  (24  h) 4/32  (13%) 9/31  (29%
:LWKGUDZDOGXHWRLQVXI¿FLHQWSDLQUHOLHI 2/32  (6  %) 7/32  (23%)
'DWDH[SUHVVHGDVPHDQFRQ¿GHQFHLQWHUYDO1RVWDWLVWLFDOO\VLJQL¿FDQWGLIIHUHQFHZDVUHDFKHGIRU
any  variable.  VAS,  visual  analogue  scale
In  a  study  (131)  where  the  effects  of  tramadol  were  compared  with  those  of  morphine  via  PCA,  
Hadi  and  colleagues    found  no  differences  in  pain  relief  or  side  effects.  Some  studies  have  indi-­
cated  that  oral  tramadol  lacks  analgesic  effect  in  the  postoperative  situation  (125,  132).  Subopti-­
mal  doses  of  tramadol  may  have  contributed  to  this  outcome.  Despite  the  higher  dose  of  morphine  
used  by  the  patients,  clinically  acceptable  analgesia  was  hard  to  achieve  with  intravenous  mor-­
phine,  either  with  or  without  tramadol.  Many  patients  were  either  in  pain  or  asleep.
Hence,  this  controlled  clinical  trial  demonstrated  that  neither  intravenous  morphine  by  PCA  nor  
the  combination  of  morphine  by  PCA  with  tramadol  resulted  in  clinically  acceptable  pain  relief  in  
patients  with  pain  after  TKA  surgery.  In  consequence  the  combination  of  tramadol  and  morphine  




gery  but  probably  also  for  the  prevention  of  persistent  pain  in  predisposed  patients.
PAIN  AND  PREDICTION  OF  PAIN  18  MONTHS  AFTER  TKA
18  months  after  TKA  pain  at  rest  and  pain  with  movement  was  assessed  for  63  and  62  patients  re-­
spectively.  The  mean  VAS  scores  were  0.5  (median  0;;  SD  1.3)  for  pain  at  rest  and  1.7  (median  1;;  
SD  3.8)  for  pain  with  movement.  21  (34%)  patients  had  no  pain  at  rest  or  with  movement.  Fifteen  
(22%)  of  the  patients  still  had  pain  at  rest  (range  1-­6)  and  41  (66%)  on  motion  (range  1-­8).  The  
UHVXOWVRIWKHSUHVHQWVWXG\FRQ¿UPWKHHIIHFWLYHQHVVRIWKH7.$LQWKHWUHDWPHQWRISDLQLQ2$
However,  18  months  after  TKA  as  many  as  eleven  patients  (16%)  reported  VAS  scores  equal  to  or  
PRUHWKDQIRUSDLQDWUHVWRUZLWKPRYHPHQW7KLVSHUFHQWDJHRISDWLHQWVQRWVDWLV¿HGZLWKWKH
TKA,  is  comparable  to  that  reported  by  others  (134).  By  identifying  preoperative  factors  related  
WRDSRRURXWFRPHVHOHFWLRQFULWHULDPLJKWEHUH¿QHG7RHQDEOHDQDO\VLVRIWKHSUHGLFWLYHYDOXH
of  preoperative  features  of  OA,  pain  18  months  postoperatively  was  assessed.  
  
7KUHHRIWKHSUHRSHUDWLYHYDULDEOHVLHSDLQDWUHVWDFFRUGLQJWR9$6Ȥ S VHQ-­




tion,  namely  pain  at  rest  and  pain  threshold  (Table  9);;  the  greater  the  pain  at  rest  and  the  lower  the  
pain  threshold  before  surgery  the  worse  the  outcome  in  terms  of  persisting  pain  at  rest.  Notably,  
pain  with  movement  at  18  months  was  not  related  to  any  of  the  tested  predictor  variables.  Nor  was  
WKHUDGLRJUDSKLFJUDGHRI2$RUWKHKLVWRORJLFDOJUDGHRILQÀDPPDWLRQLQWKHV\QRYLDOPHPEUDQH
of  any  value  for  the  prediction  of  pain  intensity  18  months  after  TKA.
  
7DEOH  Odds  ratios  (OR)  for  variables  predicting  a  poor  outcome,  i.e.  a  high  score  for  pain
at  rest  18  months  postoperatively.
Predictive  variables B* S.E.  † p OR 95%  CI  ‡
Preoperative  pain  at  rest  (VAS)§ 1.87 0.72 0.009 6.48 1.32  –  31.96
Preoperative  pain  threshold  
(Pain  Matcher®)
2.22 0.87 0.010 9.19 1.69  –  50.07
Constant  (y-­intercept) -­3.76 0.96 0.000 -­ -­
B,  slope  of  the  regression  equation  
†  SE,  standard  error  
Á&,FRQ¿GHQFHLQWHUYDO
§  VAS,  visual  analogue  scale
Since  acute  postoperative  pain  has  been  shown  to  predict  persistent  postsurgical  pain  (109)  it  was  
GHFLGHGWRXVHWKHPHDQVRIWKH9$6VFRUHVGHWHUPLQHGGXULQJWKH¿UVWSRVWRSHUDWLYHKRXUV
and  relate  these  values  to  the  outcome  in  term  of  pain  18  months  after  TKA.  A  tendency  was  
found  for  patients  with  severe  acute  postoperative  pain  to  be  at  higher  risk  of  persistent  pain  at  
rest,  but  not  with  movement  18  months  after  TKA.  
Suggested  risk  factors  of  persistent  postsurgical  pain  include  female  gender,  low  age,  intensity  
of  preoperative  and  acute  postoperative  pain,  psychic  vulnerability,  and  a  surgical  approach  that  
entails  an  increased  risk  of  nerve  damage  (109).  In  accordance  with  the  results  of  Bourne  and  
colleagues(135),  preoperative  pain  at  rest  in  the  present  study  was  found  to  be  associated  with  a  
ZRUVHRXWFRPHDIWHU7.$$QRWKHU¿QGLQJLQOLQHZLWKWKHUHSRUWRI1LHOVHQHWDORQFDHVDU-­
ean  section  was  that  a  low  preoperative  pain  threshold  to  an  electrical  stimulus  predicted  persis-­
tent  postsurgical  pain.  Also,  Werner  (136)  in  a  review  concluded  that  QST  has  a  higher  predictive  
value  with  regard  to  postsurgical  pain  than  psychosocial  factors.
In  a  previous  study  by  Pritchett  (137),  the  level  of  Substance  P  (SP)  was  determined  in  the  syn-­
RYLDOÀXLGRISDWLHQWVVFKHGXOHGIRU7.$*RRGRUH[FHOOHQWSDLQUHOLHIZDVDFKLHYHGLQRI
patients  with  an  elevated  preoperative  level  of  SP  and  in  61%  of  those  with  a  normal  preoperative  
level.  It  turned  out  that  if  surgery  had  been  done  only  on  patients  with  a  high  level  of  SP,  presum-­
DEO\UHÀHFWLQJWKHQRFLFHSWLYHFRPSRQHQWRISDLQPRVWFDVHVRISHUVLVWHQWSDLQZRXOGKDYHEHHQ
avoided.  
It  appears  that  biological  markers  may  be  of  value  in  predicting  persistent  postsurgical  pain.  It  
may  prove  that  patients  with  a  certain  biological  predisposition  may  develop  a  central  sensitiza-­





some  cases.  Alternatively,  preventive  measures  could  be  applied  before  and  after  surgery.  Hy-­
pothetically,  TKA  relieves  nociceptive  pain,  whereas  the  effect  on  neuropathic  pain  and  central  
sensitization  is  more  unpredictable.
PREDICTION  OF  CHANGE  IN  PAIN  FROM  PRE-­  TO  18  MONTHS  
POSTOPERATIVELY
It  has  been  proposed  that  the  outcome  after  TKA  should  not  only  be  based  on  postoperative  pain  
scores  but  also  on  absolute  and  relative  change  in  pain  (135).  By  calculating  absolute  and  relative  
changes  in  pain,  a  shift  was  made  from  inter-­  to  intra-­individual  comparisons.  This  was  done  to  
avoid  the  obvious  bias  of  comparing  pain  scores  between  individuals,  which  is  highly  dependent  
on  each  individual’s  unique  interpretation  of  pain.
  
The  mean  change  in  pain,  in  absolute  terms,  was  -­2.4  (95%  CI  -­2.97  to  -­1.92)  for  pain  at  rest  and  
-­5.3  (95%  CI  -­5.91  to  -­4.65)  for  pain  with  movement.  The  mean  change  in  pain  score  in  relative  
terms  was  -­53%  (95%  CI  -­0.66  to  -­0.40)  for  pain  at  rest  and  -­64%  (95%  CI  -­0.57  to  -­0.71)  for  pain  
with  movement.  Notably,  four  out  of  63  patients  at  18  months  postoperatively  scored  higher  for  
pain  at  rest  compared  to  the  preoperative  assessments  and  two  out  of  62  patients  scored  higher  
for  pain  with  movement;;  one  of  the  two  scored  higher  for  pain  both  at  rest  and  with  movement.  
$OWKRXJKWKHDYHUDJHFKDQJHLQSDLQERWKDWUHVWDQGZLWKPRYHPHQW9$6ZDVFOLQLFDOO\VLJQL¿-­
cant,  (119,  138)  patients  scheduled  for  TKA  should  be  informed  that  the  main  gain  to  be  expected  
from  the  procedure  is  relief  of  pain  with  movement.
$VGHVFULEHGDERYH WKHJUDGHRI UDGLRJUDSKLFDQGKLVWRORJLFDOFKDQJHVZHUHQRW VLJQL¿FDQWO\
related  to  the  mean  pain  intensities  at  rest  or  with  movement  preoperatively,  nor  at  18  months  
DIWHU7.$+RZHYHUDKLJKVFRUHIRUUDGLRJUDSKLF2$ZDVIRXQGWRFRUUHODWHVLJQL¿FDQWO\WRD
UHOLHIRISDLQZLWKPRYHPHQWERWKLQDEVROXWHDQGUHODWLYHWHUPVUHÀHFWLQJWKHSUHGLFWLYHYDOXHRI
radiographic  grade  of  OA.  
7KLVUHODWLRQVKLSZRXOGQRWKDYHEHHQGHWHFWHGLIWKHDQDO\VLVKDGEHHQFRQ¿QHGWRWKHSRVWRS-­
erative  pain  scores.  Instead  the  predictive  value  of  radiographic  grade  became  evident  when  the  
change  in  pain  from  pre-­  to  postoperative  was  recorded;;  the  higher  the  radiographic  grade  the  
greater  the  relief  of  pain  with  movement.  From  the  observations  made  we  suggest  that  evaluation  
RIWKHRXWFRPHDIWHUMRLQWUHSODFHPHQWVKRXOGEHEDVHGRQLQWUDLQGLYLGXDOFKDQJHIURPSUHWR
postoperative  scores  for  statistical  analysis.  Most  importantly,  follow  up  studies  on  pain  relief  by  
MRLQWUHSODFHPHQWVKRXOGFRQVLGHUSDLQDWUHVWDQGSDLQZLWKPRYHPHQWVHSDUDWHO\
THE  EFFECT  OF  TRAMADOL  ON  PAIN  18  MONTHS  AFTER  TKA
In  paper  IV  a  test  was  conducted  to  assess  whether  tramadol  administered  for  24  hours  directly  
postoperatively  as  add-­on   to   intravenous  morphine  via  PCA  might  prevent  persistent  pain  18  
months  after  TKA  as  compared  to  morphine  alone.  It  may  be  argued  that  the  chances  of  this  would  
be  limited  as  we  already  reported  that  intravenous  tramadol  in  addition  to  morphine  via  PCA  did  
QRWUHVXOWLQEHWWHUSDLQUHOLHIGXULQJWKH¿UVWSRVWRSHUDWLYHGD\+RZHYHUJDEDSHQWLQJLYHQDVD
single  preoperative  dose  before  thyroidectomy  was  found  to  prevent  persistent  postsurgical  pain  
although  it  had  no  effect  on  acute  postoperative  pain  (139).  Previous  studies  have  indicated  that  
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not  only  the  reduction  of  acute  postoperative  pain  per  se,  but  also  the  mechanism  (drug)  by  which  
this  reduction  is  achieved  has  an  impact  on  persistent  postsurgical  pain.  
,QWKHVHDUFKIRUGUXJVWKDWDFWVSHFL¿FDOO\RQFHQWUDOVHQVLWL]DWLRQWUDPDGROKDVEHHQVXJJHVWHG




causing  in  some  cases  persistent  postsurgical  pain.  Therefore  data  on  pain  at  rest  and  with  move-­
ment  18  months  after  TKA  was  compared  in  patients  randomized  to  tramadol  or  placebo.  
The  mean  VAS  scores  18  months  after  TKA  are  shown   in  Table  10.  Although  patients   in   the  
tramadol  group  scored  higher   in  pain   intensity18  months  after  TKA,   the  differences  were  not  
VWDWLVWLFDOO\VLJQL¿FDQW
  
In  summary,  the  present  study  could  not  demonstrate  that  the  combination  of  tramadol  and  mor-­
phine  was  superior  to  morphine  alone  in  preventing  persistent  pain  after  TKA.  However,  further  
investigations  exploring  the  effects  of  tramadol  administered  during  the  entire  painful  postopera-­
tive  period  should  be  made  before  the  preventive  effects  of  tramadol  on  persistent  postsurgical  
pain  can  be  discarded.
7DEOHPer  protocol  outcome  of  four  doses  of  tramadol  (100  mg)  administered  at  6h  intervals  
during  24  h
Placebo   Tramadol  
Acute  postoperative  variables (n=28) (n=22)
Mean  acute  postoperative  pain  
VAS  0-­100  (95%  C.I.)
52  (47-­57) 49  (43-­55)
Total  morphine  dose  (mg) 72  (61-­82) 51  (39-­62)*
Total  morphine  dose  (mg/kg) 0.9  (0.76-­1.04)   0.63  (0.48-­0.78)*
Outcome  at  18  months  postoperatively (n=26) (n=22rest/21move)
Pain  at  rest  VAS  0-­100  (95%  C.I.) 2  (0-­5)   9  (1-­16)  








An  obvious   limitation   of   relating   pain   intensity   to   different  morphological   features   of  OA   is  
WKHLQKHUHQWVKRUWFRPLQJRISDLQDVVHVVPHQWV'LI¿FXOWLHVLQ¿QGLQJFRUUHODWLRQVEHWZHHQSDLQ
and  different  features  of  OA  may  partly  be  explained  by  differences  in  the  interpretation  of  pain  
DPRQJLQGLYLGXDOV1RFLFHSWLYHVLJQDOVDUHVXEMHFWWRPRGXODWLRQE\FHQWUDODQGSHULSKHUDOH[-­
FLWDWRU\DQGLQKLELWRU\V\VWHPV,QDGGLWLRQSDLQDVH[SUHVVHGRQWKH9$6LVLQÀXHQFHGE\GLIIHU-­
ent  psychosocial,  economic,  cognitive  and  emotional  experiences  (141).  Yet,  VAS  is  reasonably  
reliable  (142)  and  widely  used  permitting  comparison  with  the  results  of  other  similar  studies.  To  
some  extent  the  problem  with  VAS  can  be  avoided  as  described  by  calculating  the  absolute  and  
relative  changes  in  pain  on  an  intra-­individual  level  after  a  given  intervention.
RADIOGRAPHIC  EXAMINATIONS
Although  routine  pre-­  and  postoperative  radiography  of  the  knee  was  done,  no  long  radiographs  
including  the  hip,  knee,  and  ankle,  (HKA)  were  taken  to  evaluate  alignment.  A  wide  variety  of  
mechanical  and  biological  factors  may  underlie  persistent  pain  after  TKA  (143,  144).  Presum-­




Given  the  low  incidence  of  pain  18  months  after  TKA  in  the  present  study,  the  statistical  power  in  
GHWHFWLQJDVLJQL¿FDQWHIIHFWRIWUDPDGRORQSHUVLVWHQWSDLQDIWHU7.$ZDVTXLWHOLPLWHG+RZHY-­
er,  not  even  a  tendency  toward  a  better  effect  of  tramadol  was  found.  In  our  analysis,  we  decided  
not  to  include  patients  who  withdrew  prior  to  receiving  all  4  doses  of  the  study  drug.  This  drop  
out  might  have  generated  a  bias.  Yet,  it  provided  homogenous  treatment  groups  for  comparison.  
Admittedly,  we  are  not  able  to  present  intention  to  treat  (ITT)  data  based  on  the  63  randomized  
patients.  Therefore  our  report  (paper  IV)  could  be  regarded  as  hypothesis  generating  rather  than  
hypothesis  testing.
DURATION  OF  TRAMADOL  TREATMENT
The  present  study  was  unable  to  demonstrate  an  additional  effect  of  intravenous  tramadol,  ad-­
ministered  during  24  hours  as  add-­on  to  morphine  via  PCA,  in  comparison  to  morphine  alone.  
Therefore,  it  may  be  argued  that  an  effect  on  persistent  postsurgical  pain  of  tramadol  given  during  
only  24  hours  after  TKA  would  be  unlikely.  However,  gabapentin  given  as  a  single  dose  preop-­
eratively  has  been  shown  to  prevent  persistent  postsurgical  pain  even  though  it  had  no  effect  on  






t There  is  no  correlation  between  the  intensity  of  preoperative  pain  at  rest  and  with  move-­
ment.  Preoperative  pain  at  rest,  but  not  with  movement  predicts  persistent  pain  at  rest  18  
months  after  TKA.  Therefore  pain  at  rest  and  pain  with  movement  should  be  assessed  
separately.
t The  preoperative  grade  of  radiographic  OA  does  not  correlate  with  the  intensity  of  pre-­
operative  pain  in  patients  scheduled  for  TKA,  nor  does  the  histological  grade  of  synovial  
LQÀDPPDWLRQ
t 5HOLHIRISDLQZLWKPRYHPHQWIURPSUHWRSRVWRSHUDWLYHZDVVLJQL¿FDQWO\UHODWHGWRWKH
grade  of  radiographic  OA.  Best  pain  relief  by  TKA  is  achieved  in  patients  with  severe  
radiographic  changes.  This,  however,  only  applies  to  pain  with  movement.  
t The  Pain  Matcher®  is  a  useful  tool  for  measurements  of  pain  thresholds.  Patients  with  a  
low  pain  threshold  are  at  increased  risk  of  persistent  pain  at  rest  18  months  after  TKA.  
t 7KHPHDQ9$6VFRUHGXULQJWKH¿UVWSRVWRSHUDWLYHKRXUVGRHVQRWSUHGLFWSHUVLVWHQW
pain  at  18  months  after  TKA.
  
t The  combination  of  intravenous  tramadol  100mg  x  4  and  morphine  via  PCA  does  not  of-­
fer  better  pain  relief  after  TKA  than  morphine  alone.  Nor  does  tramadol  prevent  persistent  
pain  18  months  after  surgery.
t Pain  at  rest  should  not  be  an  absolute  prerequisite  for  TKA.  Patients  scheduled  for  TKA  
should  be  informed  that  the  main  gain  to  expect  is  relief  of  pain  with  movement.
t The  evaluation  of  the  outcome  after  TKA  should  be  based  on  intra-­individual  changes  in  
pre-­  and  postoperative  pain  scores.  Most  importantly,  follow  up  studies  on  pain  relief  by  
MRLQWUHSODFHPHQWVKRXOGFRQVLGHUSDLQDWUHVWDQGSDLQZLWKPRYHPHQWVHSDUDWHO\
t (IIRUWVVKRXOGEHPDGHWRGHYHORSUHOHYDQWWRROVIRULGHQWL¿FDWLRQRISDWLHQWVDWKLJKULVN
of  persistent  pain  after  TKA  in  order  to  either  avoid  surgery  or  to  offer  pharmacological  







From  the  present  studies  as  well  as  previous  observations  it  seems  that  TKA  is  a  successful  pro-­
cedure  for  treatment  of  nociceptive  pain  in  knee  OA.  However,  a  subset  of  patients  experience  
persistent  postsurgical  pain  possibly  caused  by  a  central  sensitization.  To  identify  these  patients  
the  Pain  Matcher®  may  be  useful.
3DLQDWUHVWLVRIWHQFRQVLGHUHGDSUHUHTXLVLWHIRUMRLQWUHSODFHPHQW7KHUHVXOWVRIWKHSUHV-­
ent  study  seem  to  refute  this  view.  Instead  the  indication  for  TKA  should  be  more  restrictive  in  
patients  with  severe  pain  at  rest.  In  these  cases  QST  may  reveal  sensitization  and  prompt  phar-­
macological  intervention  to  prevent  persistent  postsurgical  pain.  In  some  patients  TKA  may  even  
be  contraindicated.  
Although  we  never   resurfaced   the  patella  we  found  no  correlation  between   the  occurrence  of  
radiographic  patello-­femoral  OA  and  pain  or  change  in  pain  18  months  after  TKA.  This  supports  




Intravenously  administered  tramadol  at  the  dose  of  100  mg  x  4  to  morphine  via  PCA  pump  does  
not  give  any  additional  pain  relief  compared  to  morphine  via  PCA  pump  alone.  Nor  does  it  of-­
fer  any  advantage  in  terms  of  side  effects.  In  addition,  the  present  study  indicates  that  morphine  
YLD3&$DV WKHVROHPHDQVRISRVWRSHUDWLYHDQDOJHVLDGRHVQRWSURYLGHVXI¿FLHQWSDLQUHOLHI
after  TKA.  Thus,  other  means  of  postoperative  analgesia  should  be  utilized  following  TKA.  In  
consequence,  the  combination  of  intravenous  tramadol  and  morphine  is  no  longer  used  in  our  
practice.  
  
When  confronted  with  a  patient  with  persistent  postsurgical  pain,  the  explanation  is  commonly  
sought  by  evaluation  of  the  radiographs  looking  for  malalignment  and  signs  of  early  loosening  
of  implants  without  considering  neuronal  mechanisms  as  the  primary  cause.  If  no  obvious  reason  
is  found  on  the  radiograph  there  commonly  remains  no  option  beyond  referral  to  a  pain  clinic.  






To  minimize  the  occurrence  of  persistent  postsurgical  pain  further  attempts  should  be  made  to  
identify  the  relevant  risk  factors.  Psychological   tests  are  already  available  and  can  give  a  hint  
about  the  need  of  preoperative  psychosocial  intervention.  Biological  markers  of  nociceptive  pain  
LQVHUXPRULQWKHV\QRYLDORUVSLQDOÀXLGDVZHOODVPDUNHUVRIFHQWUDOVHQVLWL]DWLRQFRXOGEHRQH
way  to  identify  patients  at  increased  risk.  Suggested  markers  include  BDNF  (145),  SP,  CGRP,  and  
IL-­6  (146).  Further  studies  on  the  predictive  value  of  each  of  these  factors  are  needed.
7UHDWPHQWVWKDWVSHFL¿FDOO\WDUJHWSDWKRSK\VLRORJLFDOPHFKDQLVPVNQRZQWREHLQYROYHGLQFHQ-­
tral  sensitization  are  already  available.  However,   there   is  no  consensus  about   the  use  of   these  
DJHQWV7KXVWKHUHLVDQHHGRIWHVWLQJWKHVHDJHQWVLQFRQMXQFWLRQZLWK7.$2QHWKDWKDVEHHQ
shown  to  be  more  effective  than  morphine  in  the  reduction  of  cancer  pain  is  anti-­NGF  therapy,  
which  also  lowers  the  concentration  of  markers  of  central  sensitization  (147).
One  risk  factor  for  persistent  pain,  i.e.  acute  postoperative  pain,  has  been  a  main  target  in  the  
¿HOGRISUHYHQWLYHDQDOJHVLD$JRRGHIIHFWRIORFDOLQ¿OWUDWLRQDQDOJHVLD/,$RQDFXWHSRVWRS-­
erative  pain  has  been  convincingly  shown  (148)  and  is  currently  being  tested  as  a  possible  way  
of  preventing  persistent  pain  after  surgery  (149).  Also  the  duration  of  postoperative  LIA  may  be  
RIVLJQL¿FDQFHEXWKDVVRIDUQRWEHHQLQYHVWLJDWHG7RDYRLGWKHDIIHUHQWERPEDUGPHQWGXULQJ
the  entire  painful  postoperative  period  LIA  given  during  a  longer  postoperative  period  should  be  
evaluated.  It  would  also  be  of  interest  to  test  different  analgesic  agents  given  intra-­articularly  in  
FRQMXQFWLRQZLWKVXUJHU\$QRSWLPDOLQGLYLGXDOO\GHVLJQHG³FRFNWDLO´LQWHUIHULQJZLWKVHYHUDO
mechanisms  could  be  administered  through  a  catheter  used  not  only  for  postoperative  analgesia  







Artros   i  knäleden  är  en  vanlig  orsak   till   smärta   i   rörelseapparaten.  Artros  kännetecknas  av  en  
obalans  mellan  nedbrytning  och  uppbyggnad  av  brosk  vilket  leder  till  att  brosket  successivt  bryts  
ned.  Artros  delas  in  i  primär  och  sekundär  artros.  Primär  artros  vars  utlösande  orsak  är  okänd  
GHEXWHUDURIWDVWVHQWLOLYHWRFKHQOLJW:+2¶VEHUlNQLQJDUOLGHUYDUDQQDQNYLQQDRFKYDUIMlUGH
man  över  60  år  av  någon  form  av  artros.  Sekundär  artros  drabbar  ofta  yngre  patienter  där  man  har  
HQI|UNODULQJVRPWH[HQWLGLJDUHNQlVNDGD|YHUYLNWHOOHUDQGUDVMXNGRPDU'HW¿QQVPnQJDVRP
har  artrosförändringar  som  syns  på  röntgen  men  som  inte  har  några  symtom,  och  tvärtom.  Artros  
IRUWVNULGHUOnQJVDPW'HW¿QQVlQQXLQWHQnJRWERWHPHGHO
'HW¿QQVÀHUDSUREOHPPHGDUWURV'HOVlURUVDNHQWLOOXSSNRPVWHQDYSULPlUDUWURVRNlQG'HOV
är  mekanismerna  bakom  smärttillståndet  vid   artros  ofullständigt   klarlagda.  Allt   detta  minskar  
I|UXWVlWWQLQJDUQDDWW¿QQDHWWERWHPHGHOPRWVMXNGRPHQRFKXWYHFNODVPlUWVWLOODQGHOlNHPHGHO
De  mest  framträdande  symptomen;;  smärta,  stelhet  och  svullnad  tilltar  successivt  och  kan  till  slut  
inte  behandlas  framgångsrikt  på  annat  sätt  än  med  knäprotesoperation.  Man  sågar  då  bort  ledy-­
WRUQDRFKHUVlWWHUGHPPHGHQNRQVWJMRUGOHGDYPHWDOORFKSODVW
Resultaten  efter  knäprotesoperationer  är   idag  lika  bra  som  efter  höftproteskirurgi  med  en  pro-­
tesöverlevnad  på  upp  emot  98  %  efter  10  år.  Knäprotesoperationen  är  dock  förenad  både  med  
svår  postoperativ  smärta  och  risker  för  allvarliga  komplikationer  som  infektion  och  blodpropp.  
Dessutom  drabbas  upp  till  10  %  av  oförklarad  svår  kvarstående  smärta  efter  knäoperationen.
  
En  förklaringsmodell  till  kvarstående  smärta  efter  operationer  är  så  kallad  central  sensitisering.  
0DQKDUYLVDWDWWLQWHQVLYVPlUWDHIWHURSHUDWLRQLQÀDPPDWLRQRFKQHUYVNDGRUNDQJHXSSKRYWLOO
en  kvarstående  ökad  retbarhet  hos  nerver.  Detta  leder  till  en  sänkt  smärttröskel.  Många  patienter  
med  artros  har  redan  före  operationen  tecken  på  sensitisering.  Denna  normaliseras  dock  oftast  
HIWHURSHUDWLRQHQGnGHQNURQLVNDVPlUWDQRFKLQÀDPPDWLRQHQI|UVYLQQHU'RFNYHUNDUGHW¿QQDV
individer  som  är  predisponerade  till  ett  kvarvarande  tillstånd  med  ökad  eller  tom  förvärrad  smärt-­
känslighet  efter  protesoperation.
Inom  anestesin  pågår  intensiv  forskning  kring  förebyggande  smärtlindring.  Genom  att  förhindra  
smärta   i  samband  med  operationen  tror  man  sig  kunna  minska  risken  för  att  utveckla  kronisk  
VPlUWDHIWHURSHUDWLRQHQ(QVXEVWDQVVRPLGMXUI|UV|NYLVDWVNXQQDYDUDLQWUHVVDQWLGHWWDDY-­
VHHQGHlUWUDPDGRO2PYLNXQGHLGHQWL¿HUDSDWLHQWHUPHGHQK|JULVNDWWGUDEEDVDYNYDUVWnHQGH
smärta  redan  före  operationen  skulle  man  kunna  förbehandla  dessa  patienter  så  att  mekanismerna  
bakom  kronisk  eller  persisterande  smärta  blockeras  eller  tom  undvika  operation.
MÅLSÄTTNING
Målsättningen  med  studien  var  att  undersöka  om  noggrann  analys  av  såväl  vilovärk  som  rörels-­




kvarstående  smärta  efter  operation.  Avsikten  var  också  att  undersöka  om  radiologisk  artrosgrad  
RFKKLVWRORJLVNJUDGDYLQÀDPPDWLRQLOHGHQYDUUHODWHUDGHWLOOVPlUWDI|UHRFKPnQDGHUHIWHU
operationen.  Slutligen  var  avsikten  att  undersöka  effekten  av  läkemedlet  tramadol  dels  för  behan-­
dling  av  smärta  direkt  efter  operationen  och  dels  för  att  blockera  de  mekanismer  som  leder  till  
kronisk  smärta  efter  operation.
METOD
Studien  omfattade  69  patienter  som  alla  var  planerade  för  total  knäledsprotes  på  grund  av  artros  
LNQlOHGHQ)|UHRSHUDWLRQHQ¿FNDOODSDWLHQWHUVNDWWDVLQVPlUWDLU|UHOVHRFKLYLODSnHQVnNDO-­
lad  Visuell  Analog  Skala  (VAS).  Vi  undersökte  även  smärttröskel  med  en  elektrisk  impuls  som  
|NDGHVVXFFHVVLYWPHGKMlOSDYHWW OLWHW LQVWUXPHQW3DLQ0DWFKHU VRPPDQK|OOPHOODQ WXP-­
PHQRFKSHN¿QJUHW0HGGHWWDLQVWUXPHQW¿FNlYHQSDWLHQWHUQDMlPI|UDVPlUWDQLNQlOHGHQPHG
VPlUWDQL¿QJUDUQD3nGHWWDVlWW¿FNYLQXPHULVNDYlUGHQLQWHEDUDSnVPlUWWU|VNHOQXWDQlYHQ
på  den  s.k.  matchade  smärtan  och  detektionströskel  dvs.  den  minsta  förnimmbara  impulsen.  Alla  
data  från  smärtundersökningarna  relaterades  sedan  till  varandra  och  även  till  graden  av  artros  på  
U|QWJHQELOGHQRFKJUDGHQDYLQÀDPPDWLRQLKLVWRORJLVNDVQLWWDYOHGKLQQDQ
3DWLHQWHUQDLQGHODGHVUDQGRPLVHUDGHVVHGDQVOXPSPlVVLJWLWYnJUXSSHU'HQHQD¿FNPJ
WUDPDGROYDUH WLPPHXQGHUGH I|UVWD WLPPDUQDHIWHURSHUDWLRQHQVRPWLOOlJJ WLOOPRU¿Q
YLONHWJDYVWLOODOODLQWUDYHQ|VWYLDHQSDWLHQWNRQWUROOHUDGSXPS'HQDQGUDJUXSSHQ¿FNSODFHER
LVWlOOHWI|UWUDPDGRO8QGHUWLPPDUPlWWHVPRU¿QI|UEUXNQLQJHQRFKVPlUWDQVNDWWDGHVYDUMH
timme  av  patienterna  på  en  VAS  skala.  
18  månader  efter  operationen  skattades  åter  smärtan  i  rörelse  och  i  vila  enligt  VAS.  Vi  relaterade  
VHGDQGHQQDVPlUWDWLOOGHSUHRSHUDWLYDXQGHUV|NQLQJVI\QGHQI|UDWW¿QQDIDNWRUHUVRPVNXOOH
kunna  förutspå  ett  sämre  resultat  i  form  av  kvarstående  smärta  efter  knäprotesoperation.  Vi  analy-­
serade  även  om  smärtintensiteten  under  det  första  dygnet  efter  operationen  var  av  betydelse  för  
graden  av  smärta  efter  18  månader.  Slutligen  undersökte  vi  om  tramadol  under  24  timmar  efter  
operationen  kunde  förebygga  smärta  18  månader  efter  knäledsoperationen.
RESULTAT
Huvudfynden  från  denna  undersökning  var  att  de  patienter  som  hade  mest  ont  i  vila  och  de  som  
hade  lägst  smärttröskel  före  operationen  även  hade  mer  vilovärk  18  månader  efter  operationen.  
'HVRPKDGHPHVWXWWDODGDUWURVSnU|QWJHQ¿FNVW|UVWI|UElWWULQJDYU|UHOVHVPlUWDQ'HWWDNXQGH
vi  visa  genom  att  analysera  rörelsesmärta  och  vilovärk  var  för  sig  och  beräkna  den  eventuella  
förbättringen,  dvs.  skillnaden  mellan  smärtan  före  operationen  och  den  18  månader  efter.









Patienter  med  svår  smärta  i  vila  eller  en  låg  smärttröskel  före  operationen  har  större  risk  att  drab-­
bas  av  kvarstående  smärta  efter  knäprotesoperation.  Sänkt  smärttröskel  mot  elektrisk  impuls  har  
rapporterats  vara  av  värde  för  att  påvisa  s.k.  central  sensitisering.  En  av  orsakerna  till  kvarvarande  
smärta  skulle  kunna  vara  en  ökad  retbarhet  i  nervsystemet.  
Vilovärk  anses  av  många  utgöra  huvudindikationen  för  knäprotesoperation.  Våra  resultat  talar  för  
att  vilovärk  snarare  är  en  varningssignal  som  bör  leda  till  en  utredning  om  andra  orsaker  till  smär-­
tan.  Patienten  bör  informeras  om  att  det  framförallt  är  rörelsesmärtan  som  lindras  av  ingreppet.
7UDPDGROJLYHWLUHNRPPHQGHUDGGRVWLOOVDPPDQVPHGPRU¿QLQWUDYHQ|VWKDULQJHQI|UGHOMlP-­
I|UWPHGHQEDUWPRU¿QYDGJlOOHUJUDGHQDYVPlUWOLQGULQJHOOHUELYHUNQLQJVSUR¿OYDUHVLJDNXW
postoperativt  eller  18  månader  efter  operation  med  total  knäledsprotes.
9LWURUDWWPDQLIUDPWLGHQPHGKMlOSDYELRORJLVNDPDUN|UHUQRJJUDQQVPlUWDQDO\VRFKSV\NROR-­
giska  tester  bör  kunna  karaktärisera  patienter  bättre  före  operationen  så  att  de  smärtmekanismer  
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